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The aim of the first part of the thesis is to assess if 18F Fluoro-L-Thymidine (FLT) PET-CT molecular 
imaging (as a marker of proliferation) can predict response to arginine deprivation treatment 
(ADIPEG20 combined with pemetrexed and cisplatin) earlier than anatomical imaging using CT 
(RECIST), in mesothelioma (MPM) and non-small cell lung cancer (NSCLC). FLT PET-CT imaging 
took place in a longitudinal study with scans at baseline (PET1), approximately 24 hours after the 
first dose ADIPEG20 on day 2 of cycle 1 (PET2); at the end of cycle 1 of ADIPEMCIS (PET3) on day 
16; and at the end of treatment (PET4). The baseline and end of treatment scans coincided with 
CT imaging, however, the interim scans were at different time points in n=10 MPM and n=8 
NSCLC. Using end of treatment CT as the gold standard, the response to treatment was greater 
on PET4 than CT (mean decrease of 36.5% in SUVmax compared to 21.9% decrease in RECIST 
length). Also, FLT SUVmax treatment response at PET2 predicted end of treatment response on 
CT results in nearly 2/3 cases, although on ANOVA analysis there is no statistically significant 
evidence that a decrease in proliferation (SUVmax) precedes a decrease is size (RECIST length). 
 
The aim of the second part of the thesis is to assess tumour heterogeneity changes in arginine 
deprivation treatment response in MPM using 18F Fluoro-2-deoxy-D Glucose (FDG) PET data 
from the ADAM trial (scans at baseline and 4 weeks post treatment) to see if texture features of 
FDG PET predict response better than RECIST. First-order and high-order primary tumour texture 
features were measured in n=20 patients. PET parameters, overall survival (OS), progression free 
survival (PFS) and RECIST-based treatment response (CT at 2 months) were tested by Cox and 
logistic regression analyses. From baseline to 4 weeks post therapy, there was decrease in 
skewness (mean 0.15 units, p=0.002) and kurtosis (median 0.2 units, p=0.03). None of the 
parameters at baseline or post therapy were associated with progression on RECIST. In terms of 
PFS, increase in uniformity was associated with progression (hazard ratio (HR) 2.3, p=0.02); 
increase in standard deviation (SD) was associated with decreased risk of progression (HR 0.56, 
p=0.03); and increase in SUVpeak was associated with a decreased risk of progression (HR 0.51, 
p=0.03). Texture features become more homogeneous after therapy, but this does not translate 
to improved survival. TLG at baseline was independently prognostic for OS (p=0.006); with 
additional asoociations with baseline SUVmean (p=0.03), SUVpeak (p=0.04), metabolic tumour 
volume (MTV) (p=0.01). Texture features are good at predicting the nature of the tumour. 
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Chapter 1 Introduction 
 
1.1 Lung cancer 
 
Lung cancer is a leading cause of cancer-related death.  The five-year overall survival for all stages 
is 15% (1) as most patients present at an advanced stage.  However, those with early stage 
disease can be treated with a potentially curative intent.  The majority of patients (80%) are 
clinically symptomatic and present with cough, haemoptysis, dyspnoea, chest pain or non-
resolving pneumonia; some present with features of metastatic disease such as skeletal pain or 
neurological symptoms, whereas less than 10% are asymptomatic (2).  
 
Lung cancer is classified as either non-small cell lung cancer (NSCLC, accounting for 87%) or small 
cell lung cancer (SCLC) (3).  SCLCs are usually classified as limited disease (tumour and nodal 
disease, confined to one hemithorax) or extensive disease (including extra-thoracic disease and 
distant metastases) and the primary tumour may not be visualised as a discrete entity (4). Staging 
of NSCLC is detailed below. 
 
1.1.1 Staging of NSCLC 
 
Staging of NSCLC is via the AJCC 8th edition (5).  T1 tumours are less than 3cm in size.  T1a are ≤ 
1cm, T1b are >1 cm but ≤ 2 cm, and T1c are > 2cm but ≤ 3cm.  T2 tumours are < 5cm. T2a are > 
3cm but ≤ 4cm.  T2b are > 4cm but ≤ 5cm.  T3 are > 5cm but ≤ 7cm.  T4 tumours are >7cm or 
invasive. 
 
The presence of mediastinal lymphadenopathy is important in deciding on surgical options.  Hilar 
nodes are N1.  Ipsilateral mediastinal or subcarinal nodes are N2.  Contralateral mediastinal, 




Metastatic disease is classified as M1a for intrathoracic metastases and includes pleural effusion.  
M1b disease is single-site extra-thoracic disease and M1c relates to multiple sites of extra-
thoracic disease most commonly to brain, bone, adrenals and liver. 
 
1.1.2 Imaging of NSCLC 
 
Initial investigation of lung cancer is often with a chest X-ray (CXR), however, although this is 
useful in providing preliminary confirmation of a tumour, it is inadequate for staging.   
 
Computed tomography (CT) scan of the chest is the main imaging modality in staging lung cancer.  
Primary lesions demonstrate a wide range of appearances.  They may be central or peripheral, 
smooth or spiculated, solid or cavitating, discrete or invasive. Density is variable.  Endobronchial 
tumour involvement and its distance from the carina are important in deciding a surgical 
approach.  Extent of invasion of the chest wall also affects surgical reconstructive procedures.   
 
The sensitivity of CT for chest wall invasion varies from 38 to 87% and specificity from 40 to 90% 
(6).  Invasion of the pleura is stage T3, however invasion of the great vessels, oesophagus, trachea 
or vertebral body is stage T4 and makes the tumour inoperable.  Useful CT findings include 
obliteration of the fat plane between the tumour and mediastinum.  The diagnostic accuracy for 
predicting mediastinal invasion on CT is 56 to 89%. 
 
The size of nodes is used to distinguish between benign and malignant nodal disease on CT and 
commonly a short axis diameter of more than 1cm is considered to be malignant.  CT cannot 
reliably characterise enlarged inflammatory nodes or malignant nodes smaller than 1cm.  The 
sensitivity of CT in evaluating mediastinal nodal disease is 60 to 83% and the specificity is 77 to 
82% (7)(8). 
 
Intrathoracic metastases are detected on CT with no additional imaging being required to detect 
pleural and pericardial effusions or lung nodules.  Adrenal metastases can be differentiated from 




Magnetic Resonance Imaging (MRI) has a limited role in staging lung cancer but can be used to 
determine T stage and shows a wide range of sensitivity (63 to 90%) and specificity (84 to 86%) 
(9) in determining chest wall invasion.  The diagnostic accuracy for predicting mediastinal 
invasion varies from 50 to 93% on MRI.  It is, however, useful in characterising metastases, 
particularly indeterminate adrenal lesions and superior to CT in the evaluation of brain 
metastases (10) including detecting brain lesions in asymptomatic patients.  It is also useful to 
diagnose involvement of the brachial plexus or spinal canal.   
 
Positron Emission Tomography (PET) combined with low-dose CT for attenuation correction and 
anatomical localisation is a molecular imaging technique (PET-CT). Use of PET-CT in thoracic 







Malignant pleural mesothelioma (MPM) is an uncommon malignancy which arises from the 
pleura or very occasionally, pericardium or peritoneum. It can invade both visceral and parietal 
pleura and often extends to adjacent structures. It is associated with prior asbestos exposure 
(11). Patients usually present with cough, dyspnoea, chest pain, cough, and weight loss.  
 
The prognosis is poor, with a median survival time of 12 months after diagnosis (12). Reduced 
survival time is associated with intrathoracic lymph node metastases, distant metastatic disease, 
and extensive pleural involvement (13). MPM has three major subtypes: epithelial is the most 
common subtype (accounting for 60% MPM); sarcomatoid is the most aggressive (accounting for 
10% MPM); biphasic tumours show elements of both epithelial and sarcomatoid subtypes. 
 
1.2.1 Staging of MPM 
 
Staging of MPM is using the AJCC 8th edition (14). T1 tumours are limited to the ipsilateral parietal 
pleura (including mediastinal and diaphragmatic pleura) with or without involvement of visceral 
pleura. Survival analysis of the different T categories showed no significant difference in 
categories T1a and T1b. This has resulted in a collapse of categories T1a and T1b (from the 7th 
edition) into one category T1 (although tumour thickness is significantly associated with overall 
survival). T2-4 tumour staging is unchanged from the 7th edition. T2 tumours involve each of the 
ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least 
either involvement of the diaphragmatic muscle or extension into lung parenchyma. T3 tumours 
are locally advanced but potentially resectable. There is at least involvement of the endothoracic 
fascia, extension into the mediastinal fat, extension into the soft tissue of the chest wall or non-
transmural involvement of the pericardium. With locally advanced tumours, it is important to 
distinguish between T3 (potentially resectable) and T4 (technically unresectable) disease. T4 
tumours have extension to contralateral pleura or peritoneum.  
There has been a major revision in nodal staging with the removal of category N3.  Both 
intrapleural and extrapleural (N1 and N2 in the seventh edition) are now combined into a single 
category N1. Lymph nodes that were previously categorized as N3 are now considered N2. These 
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include contralateral internal mammary as well as ipsilateral or contralateral supraclavicular 
lymph nodes and contralateral mediastinal nodes.  
M1 disease is any distant metastasis (and no metastases is M0).  
 
1.2.2 Imaging of MPM 
 
CT is the primary imaging modality used for evaluation of MPM. Key CT findings that suggest the 
presence of MPM include pleural effusion, nodular pleural thickening and interlobar fissure 
thickening. Growth typically leads to tumoural encasement of the lung with a rind like 
appearance. Calcified pleural plaques are found at CT in approximately 20% of patients and may 
become engulfed by the primary tumour. There may be contraction of the affected hemithorax 
with associated ipsilateral mediastinal shift and elevation of the ipsilateral hemidiaphragm.  
 
The presence of a soft-tissue mass that surrounds more than 50% of the circumference of a 
vascular structure is strong evidence of invasion. Chest wall involvement may manifest as 
obliteration of extrapleural fat planes, invasion of intercostal muscles, displacement of ribs, or 
bone destruction, although, irregularity of the interface between the chest wall and the tumour 
is not a reliable predictor of chest wall invasion. MPM can extend into the chest wall via needle 
biopsy and chest tube tracks or surgical scars. 
 
Transdiaphragmatic extension of MPM is suggested by a soft-tissue mass that encases the 
hemidiaphragm, whereas if there is a clear fat plane between the diaphragm and adjacent 
abdominal organs and a smooth diaphragmatic contour, this indicates that the tumour is limited 
to the thorax. Pulmonary metastases can be nodules or masses and rarely diffuse military 
nodules may be identified (15). 
 
MRI imaging can provide additional staging information in patients with potentially resectable 
disease. MPM is typically iso- or slightly hyperintense on T1-weighted images and moderately 
hyperintense on T2-weighted images. It enhances with gadolinium contrast. The superior 
contrast resolution of MRI imaging can allow improved detection of tumour extension, especially 
to the chest wall and diaphragm, hence better prediction of overall respectability (15). It is 
superior to CT in detecting invasion of the diaphragm and invasion of endothoracic fascia or a 
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single chest wall focus and in most useful in patients with an allergy to iodine contrast (16).  FDG 





1.3 Arginine auxotrophy in cancer cells, arginosuccinate synthetase 
(ASS1) and clinical use in cancer therapy 
 
Arginine is a non-essential amino acid which is not required for the growth of most human cells, 
however it is critical for the growth of human cancers (17). Arginine is involved in multiple diverse 
aspects of tumour metabolism, including protein synthesis, as well as synthesis of nitric oxide, 
polyamines, nucleotides, proline and glutamate (Figure 1). 
 
A recognised rate limiting step in arginine synthesis is down regulation of the enzyme 
arginosuccinate synthetase (ASS1) (part of the urea cycle), which catalyzes the conversion of 
citrulline and aspartic acid into argininosuccinate, which is then converted into arginine and 
fumaric acid by argininosuccinate lyase (ASL). This results in dependence on extracellular 
arginine, due  to the inability to synthesise arginine (auxotropy) (17).   
 
Normal cells derived from liver, kidney and testes could grow in medium depleted of arginine 
but supplemented with citrulline, while tumour cells from these organs could not (18). This 
implies that certain tumour cells could not re-synthesize arginine from citrulline. It was 
hypothesised that cells auxotrophic for arginine might lack ASS1 or ASL and subsequently shown 
that certain cancer cell lines and human cancer tissue specimens lack significant expression of 
ASS1 (19)(20)(21).  
 
Some tumour cells are auxotrophic for arginine. ASS1 deficiency has been identified across the 
spectrum of haematological, epithelial and mesenchymal tumours, however regulation and 
expression of the enzyme displays significant variability and is tissue-specific. ASS1 loss is due 
partly to epigenetic silencing of the ASS1 promoter. Methylation-dependent silencing of the ASS1 
promoter has been identified as a mechanism of gene repression in a subset of ASS1-deficient 
arginine auxotrophic solid and haematological tumours (22)(23)(24)  
 
Methylation-dependent silencing of the ASS1 promoter reported in mesothelioma and bladder 
cancer cell lines confers exquisite sensitivity to the arginine-lowering agents, arginine deiminase 
or arginase. In pancreatic malignancy, there was also no increase in ASS1 (25). In contrast, ASS1 
is induced rapidly in tumour cell lines without ASS1 promoter methylation limiting the 
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applicability of arginine deprivation under these circumstances, particularly as a monotherapy 
(26).  
 
Argininosuccinate lyase  (ASL), which is downstream of ASS1 and converts argininosuccinate into 
arginine and fumarate, has a secondary role in modulating tumoural arginine auxotrophy and 
sensitivity to arginine depletors in cancers including glioblastoma multiforme (27). Moreover, 
while the significance for ASS1 loss in cancer is presently unclear, several groups have revealed 
an association with worse clinical outcome and shorter metastasis-free survival in ovarian 
carcinoma, osteosarcoma, lymphoma, bladder cancer and myxofibrosarcoma 
(23)(28)(24)(29)(30).   
 
There is emerging evidence of resistance to arginine deprivation in cancer. Several mechanisms 
may reduce the efficacy of arginine depleting enzymes for cancer therapy, including ASS1 
upregulation; autophagy; stromal-tumour cell metabolic co-operation; and anti-drug antibodies 
(for example to ADI-PEG 20). Approaches to overcoming resistance include combining arginine 
depletors with chemotherapy, human (non-antigenic) arginases, and autophagy modulators 
such as chloroquine (26). 
 
Arginine is a substrate for a diverse array of metabolic and inflammatory pathways in health and 
disease. It may be sourced via the cationic amino acid transporter, ASS1, or autophagy. 
Reprogramming of the arginine metabolome via inactivation or upregulation of ASS1 results in 
differential effects on tumourigenesis. T cells also need arginine for proliferation, T cell receptor 
(TCR) expression, and development of memory. While arginine deprivation has been shown to 
impede proliferation and cell cycle progression of activated T cells, in vitro this effect can be 














Key enzymes:  
1 arginase;  
2 ornithine transcarbamylase(OTC);  
3 argininosuccinate synthetase (ASS1);  
4 argininosuccinate lyase;  
5 nitric oxide synthase;  
6 ornithine decarboxylase;  
7 pyrroline-5-carboxylate reductase;  
8 pyrroline-5-carboxylate dehydrogenase;  
9 proline oxidase (dehydrogenase);  
10 ornithine aminotransferase;  
11pyrroline-5-carboxylate synthase;  
12 arginine decarboxylase 
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1.4 ADI-PEG 20 and clinical cancer therapy 
 
ADI-PEG 20, or Pegargiminase (PEG-arginine deiminase; Polaris Group) is a bacterial enzyme that 
degrades the amino acid, arginine. The active ingredient is arginine deiminase (ADI), which is 
formulated with polyethylene glycol (PEG) of 20,000 molecular weight (PEG 20). Investigators 
reported that certain tumour cell lines could not be maintained in medium contaminated with 
Mycoplasma species and that the killing of tumour cells under these conditions was associated 
with arginine depletion (32)(33). Further studies have shown that the depletion of arginine by 
Mycoplasma was due to the activity of the enzyme arginine deiminase (ADI), which is not present 
in mammalian cells (34).  
 
As a result of these observations regarding the potential anti-cancer activity of arginine 
depletion, interest was focused on the development of ADI as a drug. The enzyme was cloned 
from Mycoplasma hominis, expressed in E. coli and subsequently conjugated to polyethylene 
glycol (PEG) (35)(36) as the ADI alone can cause severe allergy whereas conjugation with PEG 
makes this enzyme less antigenic.  It was determined that synthesis of pegylated arginine 
deiminase (ADI-PEG) with PEG of 20,000 molecular weight (mw) via a succinimidyl succinate 
linker (ADI-PEG 20) provided the optimal combination of enhanced half-life and diminished 
immunogenicity, as well as ease and yield of manufacture. Hence, ADI-PEG 20 is an arginine 
lowering drug used in ASS1-negative tumours which has been used in phase I and II trials. 
 
Several monotherapy clinical cancer studies of ADI-PEG 20 revealed safety and promising early 
activity despite the antigenic properties of a mycoplasma-derived enzyme , including patients 
with hepatocellular carcinoma (HCC) and melanoma, which showed low toxicity and evidence of 
efficacy (37) (38). However, a recent phase 3 study of ADI-PEG 20 versus placebo in patients with 
post-sorafenib relapse did not demonstrate an overall survival benefit in second line setting for 
HCC.  
 
Post-hoc analyses revealed that ASS1 was upregulated by sorafenib and may have influenced 
patient outcome (39). In contrast, a modest improvement in progression-free survival in a 
randomized phase 2 study in patients with ASS1-deficient mesothelioma versus best supportive 
care alone was reported in the ADAM (ADI-PEG 20 in Patients With Malignant Pleural 
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Mesothelioma, NCT01279967) trial highlighting a need for patient selection in future studies 
(40). ASS1 was prognostic with ASS1 deficient disease conferring a worse survival compared to 
ASS1 proficient disease. Other studies looking at ADI-PEG 20 plus nab-paclitaxel and gemcitabine 
in patients with advanced pancreatic adenocarcinoma showed therapy was well tolerated (41). 
 
Preliminary results from a phase 1 dose-escalation study of pegylated arginine deiminase, 
cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1–deficient thoracic 
cancers (TRAP, NCT02029690) showed target engagement with depletion of arginine was 
maintained throughout treatment with no dose-limiting toxicities (42) and 100% disease control 
(78% partial response) in 9 patients. To minimise resistance to ADI PEG 20, this was used in 
combination with cisplatin and pemetrexed. Cisplatin is a platinum based chemotherapy and 
pemetrexed is an anti-folate drug which targets folate dependent enzymes, such as thymidylate 
synthase (TS).  
 
Early phase clinical studies of several non-antigenic pegylated arginases are underway and 
further testing will reveal how the differential catalysis of arginine into ornithine and urea will 






1.5 18F Fluoro-2-deoxy-D Glucose (FDG) PET-CT imaging in thoracic 
malignancy 
 
FDG positron emission tomography with computed tomography (FDG PET-CT) is regarded as 
standard of care in the management of NSCLC and SPN. The F18 molecule is a positron-emitter 
gives rise to high energy photons with 511 keV, from produce the image. The FDG molecule is a 
glucose analogue which enters cells and remains trapped within the cell. It competes for GLUT 
receptors with glucose in blood and hence the patient needs to starve for 4-6 hours to maximise 
FDG uptake. The low dose CT is primarily for attenuation correction of the F18 photons, however, 
is also useful for anatomical localisation (43).  
 
1.5.1 PET-CT scanner and imaging principles 
 
PET-CT is a scanning technique which incorporates PET (positron emission tomography), where 
a radioactive molecule (which gives the “image”) is labelled with a biological molecule (which 
determines the distribution) and low dose CT (for attenuation correction of the PET image and 
anatomical localisation). 
 
Bombarding target material with protons that have been accelerated in a cyclotron produces 
positron-emitting radionuclides.  PET is based on the detection of gamma (γ) photons released 
from such radionuclides (for example fluorine-18, carbon-11, and oxygen-15). The emitted 
positrons undergo annihilation with electrons (Figure 2) (44). The photons thus released have 
energies of 511 keV (0.511 MeV) and are detected by coincidence imaging as they strike 
scintillation crystals made of bismuth germinate (BGO), lutetium oxyorthosilicate (LSO), or 
gadolinium silicate (GSO). The value 511 keV represents the energy equivalent of the mass of an 













Fluorine- 18 (F-18) is the most commonly used positron emitter in imaging. It is produced by 
bombarding O-18–enriched water with high-energy protons. Negatively charged hydrogen ions 
are accelerated in a cyclotron until they gain approximately 8 MeV of energy, then the orbital 
electrons from the ion are removed. The resultant high-energy positive hydrogen ions (H+ , or 
proton beam) is directed toward a target chamber that contains the stable O-18–enriched water 
molecules.  
 
The protons undergo a nuclear reaction to form hydrogen (F-18) fluoride: 
H2(O-18) + H-1 + energy → H2(F-18).  
 
O-18 and F-18 are isobars, so have the same mass number (A= nucleons) but different atomic 
numbers (Z = 8 for oxygen and 9 for fluorine). 
 
F-18 is an unstable radioisotope and has a half-life of 109 minutes. It decays by beta-plus 
emission or electron capture and emits a neutrino (ν) and a positron β+: 
F-18 → O-18 + β+ + ν  
 
The positron annihilates with an electron to release energy in the form of coincident photons, 
which move in opposite directions (180 degrees): 
β+ + e- →→→ (annihila on reac on) →→→ 511keV γ + 511keV γ  
 
Positrons (β+) released from the nucleus 
annihilate with electrons (β-), releasing two 
coincidence 511-keV photons 
(γ), which are detected by scintillation 
crystals (blue rectangles).  
N = neutron, 
P = proton. 
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By changing the target, other positron emitting radionuclides can be produced. 
The F-18 is labelled with a biological molecule, most commonly FDG, a glucose analogue in an 
automated computer controlled radiochemical process. The F-18 FDG thus produced is a sterile, 
non-pyrogenic, colourless liquid, with residual solvent of less than 0.04% and radioactive purity 
is greater than 95%. After local quality control procedures, this can be injected into the patient.  
 
When the patient lies on the PET-CT scanner, it is the annihilation gamma photons which are 
detected by scintillation crystals coupled to photomultiplier tubes (PMTs). These crystals are 
often composed of bismuth germinate (BGO), cerium doped lutetium oxyorthosilicate (LSO), or 
cerium-doped gadolinium silicate (GSO), which have very high densities and atomic numbers. An 
ideal crystal has high stopping power and light output and fast decay time. 
 
The absorption efficiency of BGO crystals is greater than that of LSO crystals due to its higher 
effective atomic number; however, LSO crystals emit 5 times as much light as BGO crystals, and 
the decay time for LSO is lower at 40 nsec (compared with 300 nsec for BGO), which enables the 
necessary counts or scintillation events required for image formation to be shorter with LSO 
crystals. Each detector is coupled to 4 photomultiplier tubes and they are arranged in a ring 
geometry with as many as 250 blocks in a ring (Figure 3). 
 
Figure 3. PET-CT ring detector system 
 
PET-CT scanner shows the PET ring detector system (red ring). There are up to 250 block 
detectors in the ring. Drawing shows a detector block with 8 x 8 smaller scintillation 
crystals (green and orange rectangles) linked to four photomultiplier tubes (blue circles). 
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The 511-keV gamma photons emitted opposite to each other easily penetrate soft tissues. The 
point of annihilation of a positron is not necessarily equidistant from the detector ring for both 
annihilation photons; therefore, although two photons may be coincident, they might not be 
detected at the same time by two detectors (Figure 4). Therefore, photons interacting with 
detectors within a set time window are considered to be “in coincidence.” The window for this 
coincidence detection is typically 6–12 ns. Photons outside this time window are considered as 
single events and discarded by the coincidence circuit. As many as 99% of the photons detected 
may be rejected. 
 





Time-of-fight (TOF) is a method of measuring distance based on time difference between 
emission and detection. TOF differences between two photons stopped in two detectors of the 
PET scanner are used to determine if the photons are in “time coincidence”, and, therefore, 
associated with the annihilation of a positron–electron pair. If the detection time difference 
between two photons is smaller than a coincidence window (traditionally 4–10 ns), the two 
events are considered physically associated to the same annihilation event. A line-of-response 
(LOR) joining the two detectors is drawn, and the source of the positron is assumed to be located 
in a undetermined position along the line (45). To generate 3D images, coincident LORs are 
detected and recorded at many angles and tomographic images are generated through filtered 
back projection or iterative reconstruction. The point of origin of the annihilation event is where 
these lines intersect. In TOF, for each annihilation event, the actual time difference in arrival time 
Although the photons emitted by annihilation points A and C 
are coincident, the distances that the coincident photons a and 
a1 and c and c1 will travel before they reach the scintillation 
crystals are different. There is a predetermined time window 
within which detected photons are considered to be in 
coincidence. Therefore, even though photons a and a1 and c 
and c1 are coincident, they will be electronically rejected as 
non-coincident. However, the coincident photons from point B 
are likely to reach the scintillation crystals within the time 
window and will be accepted as coincident. 
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between two coincident photons is also measured during coincident events to more accurately 
identify distance from annihilation event to detector. Hence, TPF scanners are characterized by 
a more accurate measurement of the TOF difference, which allows better localization of the 
source of annihilation along the LOR. 
 
The PET scanner is located behind the CT scanner and housed in the same extended-length 
gantry (Figure 5). PET is performed following the CT study without moving the patient. 
Approximately 6 to 7 bed positions are planned in the three-dimensional acquisition mode for 
scanning the entire patient 3-4 minutes at each bed position. 
 




As gamma photons traverse the patient, they are attenuated. The half value layer of 511keV 
photons in tissue is 7cm. Therefore, photons originating in the centre of the body are attenuated 
more than the photons originating at the edge and hence central regions appear relatively less 
“bright” than peripheries and there appears to be activity in the skin, unless an attenuation 
correction is performed. Correct factors for attenuation correction of the PET study are obtained 
from the low dose CT.  As the CT is acquired with a much lower energy than the PET, a procedure 
to convert the measured attenuation coefficients to 511keV is required. The CT attenuation 
correction (CTAC) is usually accomplished by assuming a simple bilinear relationship between 
Hybrid PET-CT scanner shows 
the PET (P) and CT (C) components. 
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the CT number in Hounsfield Unit (HU, linearly related to the CT attenuation coefficient) and the 
511 keV attenuation coefficient required for PET (46) (Figure 6). 
 
Figure 6. Bilinear scaling function used to convert CT numbers (HUs) to linear attenuation values 




PET images are reconstructed using iterative algorithms, which model the statistical properties 







1.5.2 Clinical FDG PET-CT imaging  
 
18F-Fluorodeoxyglucose (FDG) is a glucose analogue which is widely used clinically to evaluate 
regional glucose metabolism in cancer and yields functional information useful for both 
diagnosing and staging cancer.  The basis for use of FDG PET-CT is the increased glucose 
consumption by cancer cells compared to normal tissue.  
 
Solitary Pulmonary Nodule 
 
A solitary pulmonary nodule (SPN) is defined as a focal round or oval lung lesion with a diameter 
smaller than 3 cm, completely surrounded by normal lung tissue, not associated with atelectasis 
or adenopathy (48). Several studies showed that PET had similar sensitivity (92–95%) but 
superior specificity (72–83%) as compared to CT (sensitivity 95%; specificity 40%) for the 
characterization of SPN [146–149] (49)(50)(51)(52), especially in excluding malignancy in small 
SPNs ( <15mm) (53).   
 
Non-Small Cell Lung Cancer 
 
FDG PET-CT is accepted as a standard imaging modality in the initial staging and diagnostic work-
up of patients with lung cancer. PET-CT is superior to PET and CT alone in T staging (88% of 
patients compared to 40% and 58%, respectively) (54).  
 
FDG PET-CT offers an improvement in diagnostic accuracy of imaging mediastinal nodal disease 
as it can differentiate reactive or inflammatory nodes from metastatic disease and can detect 
metastases in normal-sized nodes.  A meta-analysis on FDG-PET in lung cancer showed a pooled 
sensitivity of 72% and specificity of 91% for mediastinal nodal disease (55).   
In NSCLC, FDG PET-CT has better sensitivity than CT alone in the detection of locoregional disease 
(most notably mediastinal nodal staging) and distant metastases, including differentiation of 
equivocal lesions seen on conventional cross-sectional imaging.  
 
The American College of Chest Physicians (ACCP) Clinical Practice Guidelines recommends the 
use of FDG PET-CT for mediastinal and extra-thoracic staging in patients with clinical stage IB to 
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IIIB in lung cancer being treated with curative intent and it should be considered in patients with 
clinical 1A lung cancer being treated with curative intent. Minimally invasive needle techniques 
to stage the mediastinum have become increasingly accepted and are the tests of first choice to 
confirm mediastinal disease in accessible lymph node stations (56) 
 
PET-CT can help characterise pleural disease (57). FDG PET-CT performs better than bone 
scintigraphy in detecting skeletal metastases.  A recent meta-analysis shows PET-CT has 
sensitivity of 92% and specificity of 98% for diagnosing bone metastases (58) This is due to its 
ability to detect both osteolytic and sclerotic metastases and can detect asymptomatic marrow 
metastases which can be seen in up to 13% of cases of lung cancer.  However, brain metastases 
are less easily identified due to high background grey matter uptake (43). 
 
The addition of FDG PET-CT reduces the frequency of unnecessary thoracotomies by 20%.   A 
study by Fischer et al. showed that the use of  FDG PET-CT for pre-operative staging of NSCLC 
reduced both the total number of thoracotomies and the number of futile thoracotomies but did 
not affect overall mortality (59). The impact of PET on staging has shown an upstage in 16-33% 
and downstage in 6-10% of patients (60). Systematically applied PET scanning has a significant 
impact on patient management, altering diagnostic or therapeutic interventions in 72.2% of 
patients, changing staging in 22.2% of patients, and identifying serious unsuspected diagnoses in 
4.0% of patients, with potentially life-saving consequences in 2.0% (61).  
 
However, whilst this is a sensitive technique, specificity for characterising lung cancer is limited. 
Some lung malignancies such as adenocarcinomas in situ, carcinoid and well-differentiated 
adenocarcinomas may not be as metabolically active as one may expect, yielding a false negative 
finding (62).  False negative findings may also be related to small lesion size although modern 
PET cameras have a spatial resolution of 5 to 8mm. Thus false negative results may accrue due 
to low-grade or slow-growing tumours, or small lesions. 
 
False positive results occur in infection and inflammatory processes such as active tuberculosis 
and sarcoidosis due to overexpression of GLUT1 and GLUT3 transporters in the acute phase of 





The degree of metabolic activity in MPM than is significantly higher than in benign pleural 
diseases such as inflammatory pleuritis and asbestos-related pleural thickening. PET-CT has 
increased accuracy in the detection of mediastinal nodal metastases (64), but is also useful in the 
identification of occult extrathoracic metastases (65). Patients with MPM may have diffuse 
pleural thickening but only focal areas of malignancy and areas of pleural thickening may not 
correspond to areas of high metabolic activity, hence PET-CT can guide clinicians to the most 
appropriate biopsy site, which may not be apparent from CT findings alone. PET-CT may also help 
predict prognosis in patients with MPM as higher FDG uptake is associated with significantly 
shorter survival time (66). 
 
In MPM, FDG PET-CT identifies significantly more patients with nodal or distant metastatic 
disease than CT and hence may contribute to more appropriate selection of patients with MPM 
for surgery. Elliott et al. found that nodal disease was concordant to surgical histopathology in 
38/60 patients (63.3%) on PET-CT, compared to 27/60 (45%) on CT (p = 0.001). Distant 
metastases were identified uniquely on PET-CT in 8 patients and on CT only in one patient (67). 
There is limited value in using FDG PET-CT in patients who have undergone prior talc or chemical 
pleurodesis, as inflammatory response can cause increased avidity in the pleura for prolonged 
periods of time and can also result in an increase in size of the mediastinal and hilar nodes with 




FDG PET-CT is also increasingly used for radiotherapy planning in patients with NSCLC and is 
preferable to CT alone. PET-CT planning for target volumes in radiotherapy is different from the 
treatment volume. The percentage of changes recorded by PET-CT ranges from 27% to 100% and 









The main system for assessing anatomic tumour response is the Response Evaluation Criteria in 
Solid Tumours (RECIST), which is based on serial measurements using standard imaging 
techniques such as CT (70). This method relies on changes in tumour size. Two sets of response 
criteria using PET are currently available to monitor metabolic changes to anti-cancer treatment. 
The European Organization for Research and Treatment of Cancer (EORTC) criteria, the first 
metabolic criteria for solid tumours, were published in 2000 (71), and the PET Response Criteria 
in Solid Tumours (PERCIST) in 2009 (72). Although the two metabolic criteria have quite different 
approaches, tumour responses between the two criteria showed almost perfect agreement in a 
pooled analysis of several studies with different types of cancers (73). 
 
Sequential FDG PET imaging has also been investigated as a metric of response to treatment. 
Increased FDG uptake in tumours is generally correlated positively with the total tumour cell 
mass, and decrease in FDG uptake with treatment is typically associated with response to 
therapy (74)(75), not uncommonly preceding a decrease in tumour size (76).  
 
Studies have shown the sensitivity and specificity of PET for assessing histopathological response 
of NSCLC  ranging between 81% and 97% and 64% and 100%, respectively (77). Huang et al. have 
shown that standardised uptake values (SUV) and metabolic tumour volume (MTV) changes from 
two serial FDG PET-CT scans before (baseline) and after initial chemoradiotherapy (at 
approximately 28 days) allow prediction of treatment response in advanced NSCLC (78).  
 
PET-CT may be useful in assessing treatment response, with a partial metabolic response 
demonstrated at 4 weeks after arginine deprivation treatment in 46% of 39 patients (40). 
Kanemura et al. found that metabolic response assessment with FDG PET-CT was superior to 
modified RECIST for the evaluation of response to platinum-based doublet chemotherapy (3 
weekly cycles with assessment after 3 cycles )in malignant pleural mesothelioma (79). Similarly,  
Ceresoli  et  al. in a study of 20 patients  with  MPM (mostly  treated  with  pemetrexed  and  
carbo-platin) found that a decrease in metabolic response determined by SUVmax correlated 
significantly with time to progression and a trend towards longer survival, while response 
evaluation by CT was not predictive (80). Veit-Haibach et al., however, found that SUVmax was 
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not predictive of survival (81). Metabolic responses were noted in 46% patients with ASS1 
deficient mesothelioma treated with arginine deprivation therapy  (27). In the ADAM trial, FDG 
PET-CT treatment response was assessed using the EORTC criteria. This trial showed that PET-CT 
may be useful in assessing treatment response, with a partial metabolic response demonstrated 
at 4 weeks after arginine deprivation treatment in 46% of 39 patients, stable disease in 31%, 
progression in 15% and mixed response in 8%  (40).  Participants with partial metabolic response 
showed a 46% decrease in SUVmax. 
 
FDG PET-CT, however, carries with it challenges in assessing response, notably uptake of the 
radiotracer into non-malignant inflammatory cells, which can confound assessments of tumour 
response. In particular, there is  significant prolonged FDG uptake post talc pleurodesis.   
In addition, “flare” reactions and “stunning” of FDG activity levels by treatment have been 
described, which make it less than perfect in some instances as a general early metric of tumour 
response to treatment (82) and increase in FDG uptake post ADI therapy have been 
demonstrated in melanoma in mouse xenografts. There is also significant prolonged FDG uptake 




1.6 18F Fluoro-L-Thymidine (FLT) PET-CT imaging in thoracic 
malignancy 
 
There is recognition that evaluation of other aspects of abnormal cancer biology in addition to 
glucose metabolism may be more helpful in characterising tumours and predicting response to 
novel targeted cancer therapeutics. Therefore, efforts have been made to develop and evaluate 
new radiopharmaceuticals in order to improve the sensitivity and specificity of PET imaging in 
lung cancer with regards to characterisation, treatment stratification and therapeutic 
monitoring.  
 
F-18 fluoro-3-deoxy-3-L-fluorothymidine (18F-FLT) a marker of cellular proliferation and hence 
used as a proliferation tracer for PET-CT imaging. Thymidine is a native nucleoside, which is used 
by proliferating cells for DNA synthesis during the S-phase of the cell cycle and a substrate for 
thymidine kinase (TK), but is not involved in RNA synthesis.  There are two main pathways 
involved in DNA synthesis. The ‘salvage’ (exogenous) pathway recycles nucleoside precursors 
from outside the cell, and the ‘de-novo’ (endogenous) pathway methylates deoxyuridine 
monophosphate by thymidylate synthetase to thymidine monophosphate (Figure 7). As the 
precursors of the de-novo pathway (deoxyuridine, uridine and uracil) are also precursors for RNA 
synthesis, the thymidine salvage pathway is a more specific reflection of DNA synthesis (83). 
 





FLT is a thymidine analogue, where 18F replaces the OH group. It follows only the exogenous 
pathway. It generally enters the cell by Na+-dependent active nucleoside transporters and to a 
lesser extent by passive diffusion. It follows the salvage pathway of DNA synthesis and, like 
thymidine, undergoes phosphorylation by thymidine kinase1 (TK1) but it is then trapped 
intracellularly and not incorporated into DNA. FLT is a selective substrate for TK1 and hence its 
uptake correlates with the activity of TK1. TK1 is up-regulated during active DNA synthesis, such 
as in malignant cells, thus FLT uptake is a marker of active DNA synthesis (84). FLT is  
glucuronidated in the liver and at I hour post administration, 1/3 of FLT injected is diverted to 
glucuronide. 
 
Most data to date suggest that FLT is not a suitable biomarker for staging of cancers. 
FLT shows a lower accumulation in tumours than FDG as it only accumulates in the cells that are 
in the S phase of growth and demonstrates a low sensitivity for nodal staging 
This is because of the rather low fraction of tumour cells that undergo replication at a given time 
with subsequently relatively low tumour FLT uptake. There is also marked physiological uptake 
in bone marrow and liver making these tissues difficult to investigate (85). Its uptake in tumour 
cells, however, directly correlates with histopathological Ki-67 expression in NSCLC (86) and 
therefore it is a more specific oncological tracer than FDG. Its main role is in evaluating treatment 
response (87). 
 
Buck et al. compared uptake in lung cancer (NSCLC, SCLC and metastases) using both FDG and 
FLT and showed that-FLT uptake was related exclusively to malignant tumours; in contrast FDG 
uptake was seen in 4/8 benign lesions (88). Buck et al. also found that the sensitivity of FLT for 
nodal staging was unacceptably low (53%), but as there was no physiological tracer accumulation 
in the brain, it could be a suitable radiotracer for investigating brain metastases (86) and 
suggested that FLT may be the superior tracer for assessment of therapy response and outcome. 
In a similar study in 31 patients with NSCLC, Yang et al. reported that the sensitivities of FLT and 
FDG for primary lesions were 74% and 94%, respectively (p=0.003) and FDG was more sensitive 
in regional nodal staging (89). Tian et al. studied dual tracer imaging of pulmonary nodules with 
FLT and FDG in 55 patients and found this to be better than either tracer alone (90).  Each patient 
was imaged twice using FDG and FLT within 7 days. The order of 18F-FDG or 18F-FLT scanning of 
each patient was determined randomly by a binary code produced by a computer. Within 7 days, 
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the whole procedure was repeated using the alternative radiopharmaceutical. The uptake of a 
lesion was also scored qualitatively ranging from no uptake to very high uptake.  The sensitivity 
and specificity of FDG were 87.5% and 58.97% and for FLT 68.75% and 76.92%, respectively. The 
combination of dual-tracer PET-CT improved the sensitivity and specificity up to 100% and 
89.74%.  Sohn et al. studied gefitinib (an EGFR tyrosine kinase inhibitor) response in patients with 
advanced adenocarcinoma of the lung measuring changes in FLT uptake and found that activity 
on day 7 differed significantly between responders and non-responders (91). Trigonis et al. found 
that in patients with NSCLC treated with radiotherapy and imaged with FLT, that radiotherapy 
induced an early significant decrease in tracer uptake, after 5-11 treatment fractions (92). 
 
1.6.1 Rationale for use of FLT  
 
Recent preclinical work (30) has identified that ADI-PEG 20 affects both pathways of sourcing 
thymidine: in addition to suppression of the endogenous de novo thymidylate biosynthesis 
pathway (with a resulting increase in glutamine), ADI-PEG 20 also downregulates the salvage 
pathway with reduced thymidine uptake linked to a reduction in the level of TK1 (rather than an 
increased level as one would expect if just the de novo pathway was involved, i.e. 5FU, a pure TS 
inhibitor). ADI is selective, as it does not affect all amino acids. Xenograft studies have confirmed 
that ADI-PEG 20 therapy lowers FLT tumoural levels thereby providing a rationale for measuring 
tumour proliferation with FLT PET-CT imaging in patients. 
 
FLT therefore may be a more robust biomarker of early ADI-PEG 20 activity than measurement 
of tumour metabolism with FDG PET-CT, which yields an increased signal in some ADI-treated 
tumours due to enhanced glucose uptake via suppression of phosphatase and tensin homolog 
(PTEN) and activation of PI3K signalling (93). Interestingly, they also showed that FLT was not 
useful for melanomas, implying that the ASS1-negative cell type of origin is very important when 
evaluating PET tracers in the context of arginine deprivation (94). ADI-PEG 20 suppresses TS and 
dihydrofplate reductase (DHFR) protein (in mesothelioma and bladder cancer cells) and 
sensitises ASS1-negative bladder cancer (and mesothelioma) cells to the cytotoxic effects of 
pemetrexed. In addition, ADI-PEG 20 blocks thymidine uptake linked to reduced TK1protein, 





ASS1 is expressed constitutively (i.e. unstimulated or basal conditions) at high levels in most 
tissues, except within lymphoid tissue and bone marrow. However, once arginine is removed, it 
is hypothesised that lymphoid tissue and bone marrow upregulate ASS1 to make arginine for cell 
proliferation. This then results in upregulation of TK1 and hence increased FLT uptake (24). 
Arginine (and hence ASS1) is important for BM/lymphoid derived cell proliferation. 
 
Work with FLT to assess treatment response of NSCLC and mesothelioma with ADI-PEG20 in 
combination with cisplatin and pemetrexed is encouraging and has shown a significant decrease 
in tracer uptake at the end of treatment, consistent with human tumour xenograft studies of 
ADI-PEG20 and the known pharmacology of arginine depletion in ASS1-deficient tumours 
suggesting that measuring changes in proliferation with FLT are likely to be more specific than 
non-specific downstream effects of FDG (30). Pemetrexed, is an antifolate agent and antifolates 
target folate dependent enzymes, such as thymidylate synthase (TS), which are specific for the 
endogenous pathway. In particular, 5 fluorouracil, have been shown to increase FLT uptake post 
therapy as part of the salvage response to TS inhibition.  
 
Potential problems with using FLT in imaging treatment response include: 
1) high physiological uptake in liver and bone marrow; 
2) exogenous pathway only; 
3) potential “flare” from increased dependence on exogenous thymidine following anti-
folate therapy; 
4) potential increase in unconjugated FLT in plasma (as some chemotherapy agents deplete 
glucouronidate and hence less FLT is conjugated with resultant increase in FLT plasma 
fraction). 
 
The preclinical data suggests that FLT PET-CT, as a marker of proliferation, may be a better 
biomarker of treatment response than FDG PET in arginine deprivation therapy in thoracic 
malignancy and hence provides rationale for why further evaluation is required. The overall goal 





1.7 Quantifying tumour heterogeneity using radiomics 
 
Radiomics, or texture analysis,  is the “comprehensive quantification of tumour phenotypes by 
applying a large number of quantitative image features” (95). Texture analysis is a tool for 
assessing intratumoural heterogeneity and refers to mathematical methods which are applied 
to describe relationships between grey-level intensity in pixels or voxels and their position within 
an image. Texture parameters can be measured on standard clinical imaging protocols using post 
processing techniques, most commonly using a statistics based model (96), based on spatial 
distribution of pixel or voxel values calculating local features at each pixel in an image and 
deriving parameters from the distribution of local features. The statistical methods are 
categorized as first-order (one voxel); second-order (two voxel); and high-order (three or more 
voxel) statistics (97). 
 
First-order texture features describe global textural features relating to grey-level frequency 
distribution within a region of interest and are based on histogram analysis. They include mean, 
minimum and maximum intensity (SUVmean, SUVmin, SUVmax), standard deviation, skewness 
(asymmetry of the histogram) and kurtosis (peak of the histogram), first order uniformity 
(regularity) and first order entropy (randomness of grey level voxel intensities within an image) 
(98).  
 
They do not convey spatial information within the tumour as the above properties are calculated 
using individual voxel values, ignoring the spatial relationships between voxels. This group also 
includes metabolic tumour volume (MTV) and total lesion glycolysis (TLG = SUVmean x MTV). 
 
Second-order (in plane) features describe local texture features and are calculated using e.g. 
spatial grey-level dependence (GLDM) or co-occurrence matrices (GLCM) and determine how 
often a pixel of intensity finds itself within a certain relationship with another pixel of intensity. 
These include second order entropy (randomness of the matrix) and uniformity 
(orderliness/homogeneity; not to be confused with first-order entropy and uniformity), contrast 
(local variation), homogeneity, dissimilarity (difference between elements in the matrix) and 




High-order (multiplane) parameters are calculated e.g. using neighbourhood grey-tone 
(intensity) difference matrices (NGTDM) or grey- level size-zone matrices (GLSZM) and describe 
local features based on differences between each voxel and its neighbouring voxels in adjacent 
planes. These include coarseness (granularity);  contrast (dynamic range of intensity levels and 
the level of local intensity variation) and busyness (rate of intensity change within an image) (97). 
Figure 8 illustrates the differences between these different order statistics. Table 1 (below) lists 
the parameters we have evaluated in this thesis.  
 
Figure 8. Four simulations of different intensity variations (from Chicklore et al.(97)) 
 
 
First order parameters are the same for all four cases. 
Second-order features (which are derived from grey-level co-occurrence matrix with 
offset[1.0]) will be different for “a” compared to “b”, “c” and “d”, but the latter three will 
be the same. 
High-order features (derived from neighbourhood grey time difference matrices or grey- 
level size-zone matrices) will be different for all four cases. 
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Table 1. Common heterogeneity parameters (from Cook et al.(98)) 
 
Parameter Order Description 
 
SUVmax First Voxel with highest intensity 
SUVmean First Average of all pixel intensities 
SUVpeak First Maximum average SUV within a 1 cm 
 
3 spherical volume 
MTV First Metabolic tumour volume 
TLG First Total lesional glycolysis = MTV x SUV mean 
Standard 
deviation 
First Positive square root of variance (variance= variability that 
utilizes all data; average of the squared differences between 
each data value and the mean) 
Skewness First Measure of asymmetry and deviation from a normal 
distribution. Skewness ˃0: right skewed, most values 
concentrated on the left of the mean. Skewness ˂0: left 
skewed, most values concentrated on the right of the mean. 
Skewness = 0: symmetrical distribution around the mean 
Kurtosis First Describes ‘‘peaked-ness’’ of a distribution  
Kurtosis ˃3: sharper peak than a normal distribution, with 
values concentrated around the mean and thicker tails; this 
means high probability for extreme values; 
Kurtosis ˂3: flatter than a normal distribution with a wider 
peak; the probability for extreme values is less than for a 
normal distribution, and the values are spread more 
widely around the mean; 
Kurtosis = 3: normal distribution 
Entropy First Measures texture randomness or irregularity 
Uniformity First Measure regularity. 
Sum of squared elements in the ROI 
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Contrast High This value increases with the amount of local variation in 
intensity. An image is said to have a high level of contrast if 
areas of different intensity levels are clearly visible. Thus, a 
high contrast means that the intensity difference between 
neighbouring regions is large. This is usually the case when the 
dynamic range of the grey scale is large or stretched  
Coarseness High Based on differences between each voxel and the 
neighbouring voxels in adjacent image planes, it measures the 
granularity within an image; described as the most 
fundamental  property of texture. 
Busyness High A busy texture is one in which there are rapid changes in 
intensity from one pixel to its neighbour; that is the spatial 
frequency of intensity changes is very high. A higher 
value of busyness would tend to emphasise the frequency of 
spatial changes in intensity values 
Complexity High A texture has high complexity if the information content is 
high and there are many grey values present. Complexity is the 





1.7.1 Radiomics in thoracic malignancy 
 
Radiomics has shown potential in a number of tasks such as classifying lung lesions into benign 
or malignant , differentiating between primary and metastatic lesions, predicting survival  and 
response to treatment, thus showing promise towards personalized therapy in oncology 
(93)(98). Measurement of heterogeneity within medical images may reflect the underlying 
biologic environment and genetic heterogeneity within a tumour, allowing prediction of  changes 
before and during treatment (99). Beyond the relatively simple measurements of tumour uptake 
or size, there is increasing recognition that measurement of the spatial heterogeneity of FDG PET 
image characteristics can give predictive information on baseline, pretherapy, imaging in several 
solid tumours (100). CT and MRI imaging have high spatial resolution, allowing texture analysis 
in small volume tumours. However, the poorer spatial resolution of PET imaging (pixel sizes up 
to 5mm) limits the size of tumours which can be assessed (due to requirement of a reasonable 
number of adjacent pixels to be present to measure some of the texture features) (97). 
 
In NSCLC, first-order heterogeneity parameters on FDG PET, including SUV intensity-volume 
histograms, have been described as predictive for radiation therapy response (101) and pre-
therapy high order heterogeneity features (coarseness, contrast, and busyness) are associated 
with non-response to chemoradiotherapy by RECIST and with poorer prognosis (100). A study 
looking at heterogeneity features on FDG PET in NSCLC treated with erlotinib, a tyrosine kinase 
inhibitor (TKI), showed that response to treatment is associated with reduced heterogeneity on 
FDG PET and changes in first-order entropy are independently associated with overall survival 
and treatment response) (102). Histopathological mean tumour-cell density (MCD) and 
histopathological lacunarity are associated with several commonly used FDG PET-derived indices 
including SUV-lacunarity, metabolically active tumour volume, SUVmean, entropy, skewness, 
and kurtosis, which may explain the biological basis of FDG PET heterogeneity in non-small-cell 
lung cancer(103).  
 
A recent study by Bianconi et al. found significant associations between PET features, CT 
features, and histological type in NSCLC and concluded that texture analysis on PET-CT shows 
potential to differentiate between histological types in patients with non-small-cell lung cancer. 
Intra-PET analysis identified a strong positive correlation between the radiotracer uptake 
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(SUVmax, SUVmean) and its degree of variability/disorder throughout the lesion. Conversely, 
there was a strong negative correlation between the uptake (SUVmax, SUVmean) and its degree 
of uniformity. There was a positive moderate correlation between MTV and radiotracer uptake 
(SUVmax, SUVmean). Inter (PET-CT) correlation analysis identified a very strong positive 
correlation between the volume of the lesion on CT and MTV, a moderate positive correlation 
between average tissue density (CTmean) and radiotracer uptake (SUVmax, SUVmean), and 
between kurtosis on CT and MTV.  Squamous cell carcinomas had larger volume higher uptake, 
stronger PET variability and lower uniformity than the other subtypes. By contrast, 
adenocarcinomas exhibited significantly lower uptake, lower variability and higher uniformity 
than the other subtypes (104). 
 
1.7.2 Rationale for further investigation 
 
There is very little published data in MPM to determine if there is any role for textural analysis 
in FDG PET in MPM.  The only published study to date shows that FDG PET-CT parameters that 
take into account functional volume (MTV, TLG) show significant associations with survival in 













1.8 Thesis Aims and Hypothesis 
 
1.8.1 Thesis aims:  
 
To assess tumour proliferation (with FLT PET-CT) as a marker of early treatment response 
in thoracic malignancy (MPM and NSCLC) using arginine deprivation therapy (ADI-PEG 20 
combined with pemetrexed and cisplatin), as part of TRAP trial substudy.  
 
To assess tumour heterogeneity changes in arginine deprivation treatment response in 
MPM using FDG PET data from the ADAM trial with scans at baseline and 4 weeks post 
treatment. 
 
1.8.2 Scientific hypotheses: 
 
FLT PET-CT molecular imaging can predict response to arginine deprivation treatment 
(EORTC) earlier than anatomical imaging using CT in NSCLC and MPM (RECIST). 
 
Texture features of FDG PET-CT predict responders and non-responders to arginine 
deprivation treatment better than CT in MPM (and hence superior to RECIST, currently 
















TRAP was a phase 1 study (NCT02029690) in subjects with Tumours Requiring Arginine to assess 
first line ADI-PEG 20 combined with Pemetrexed and Cisplatin (ADIPEMCIS) chemotherapy. 
Informed consent was obtained for inclusion in the FLT PET-CT imaging substudy of this trial, in 
patients with thoracic malignancy (MPM and NSCLC). I was Co-Principle Investigator for this 
substudy, responsible for the PET imaging protocol, supervising and overseeing the PET studies, 
ensuring the PET studies were performed in accordance with the protocol and good clinical 
practice (GCP).  Approvals were obtained from Leeds East REC (14/YH/0090), MHRA and ARSAC 






Patients with histologically proven ASS1-deficient MPM and NSCLC (defined as >50% ASS1 loss) 
recruited into the phase 1 dose-expansion imaging substudy were chemotherapy naive, had an 
expected survival of at least 3 months, were over 18 years of age, ECOG performance status (PS) 
0-1 with adequate haematological (Hb > 9.0g/dL; absolute neutrophil count (ANC) > 1,500/µL; 




These included toxic manifestations of previous treatments, brain and spinal cord metastases, 
serologically positive for human immunodeficiency virus (HIV), serious infection, therapeutic 






Patients received the maximum tolerated dose derived from the dose-escalation study: weekly 
ADI-PEG 20 (36 mg/m2  I.M.) with standard doses of pemetrexed (500 mg/m2 I.V.) and cisplatin 
(75 mg/m2 I.V.), both given every 21 days (42). Subjects with MPM received up to a maximum of 
6 cycles of treatment every 3 weeks (i.e. up to 18 weeks). Patients achieving stable disease or 
better could continue ADI-PEG 20 monotherapy until disease progression or withdrawal. 
Subjects with NSCLC received up to a maximum of 4 cycles of treatment every 3 weeks. Subjects 
were free to discontinue the study at any time, for any reason, and without prejudice to further 
treatment. 




2.1.3 Imaging and Analysis 
 
Computed Tomography (CT) 
 
CT imaging was performed as part of routine clinical care: at baseline (CT1), after 2 cycles of 
treatment (at approximately 6 weeks, CT2) and end of treatment (@18 weeks for MPM and 12 
weeks for NSCLC, CT4). In MPM, subjects had an additional clinical CT scan after 4 cycles (CT3).  
 
CT Image Acquisition 
 
Diagnostic CTs were acquired as standard of care on a Definition AS 64 slice CT scanner (Siemens 
Healthcare, Erlangen, Germany) at St. Bartholomew’s Hospital. IV contrast-enhanced CT scans 
obtained with a minimum slice thickness of 3–5 mm were available for review. Each patient 
received 80–100 mL of IV iodinated contrast medium (iodixanol 300 or iohexol 300) injected at 
a rate of 2–3 mL/s, and scanning began after a delay of 20-25 seconds for arterial and 75–90 
seconds after injection for the portovenous phase imaging. 
 
CT Image Analysis 
 
CT response was assessed by an experienced chest radiologist (SE) using RECIST 1.1 (NSCLC) (70) 
(Table 2) and modified RECIST (MPM) criteria (106).  For modified RECIST, the tumour 
thickness perpendicular to the chest wall or mediastinum is measured in two positions at three 
separate levels on transverse cuts of CT scan. The sum of the six measurements is defined as a 
pleural unidimensional measure.  Complete response (CR) is defined as the disappearance of all 
target lesions with no evidence of tumour elsewhere; partial response (PR) is defined as at least 
a 30% reduction in the total tumour measurement; progressive disease (PD) is defined as an 
increase of at least 20% in the total tumour measurement over the nadir (lowest) measurement, 
or the appearance of one or more new lesions. Patients with stable disease (SD) were those who 





Table 2. Response assessment of CT imaging on RECIST 1.1 criteria 
 
Complete Response (CR): Disappearance of all target lesions. Any pathological lymph 
nodes (whether target or non-target) must have reduction in 
short axis to < 10 mm. 
Partial Response (PR): At least a 30% decrease in the sum of the diameters of target 
lesions, taking as reference the baseline sum diameters. 
Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target 
lesions, taking as reference the smallest sum on study (this 
includes the baseline sum if that is the smallest on study). In 
addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm. The 
appearance of one or more new lesions is also considered 
progression.  
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest 








FLT PET-CT imaging took place in a longitudinal study with scans at baseline (PET1), 
approximately 24 hours after the first dose ADI-PEG20 on day 2 of cycle 1 (PET2); at the end of 
cycle 1 of ADIPEMCIS therapy (PET3) on day 16 (2 weeks); and at the end of treatment (PET4 at 
day 120 (18 weeks) for MPM and at day 80 (12 weeks) for NSCLC). The baseline and end of 
treatment scans coincided with CT imaging, however, the interim scans were at different time 
points (Figures 9 and 10). 
 
Baseline PET-CT imaging was performed in a total of 22 patients, however 4 patients were 
subsequently excluded due to deterioration in performance status. Ten patients with 
histologically proven advanced MPM (mean age 69 +/- 7.6 years) and 8 patients with non-
squamous NSCLC (mean age 58 +/- 8.4 years) proceeded to further PET imaging. There was slight 
variation in the timing of PET scan 2 between groups due to a change in FLT tracer availability 
and scheduling: for the NSCLC group, this took place around at 28-29hrs post ADI-PEG20, rather 
than exactly 24hrs, while in the MPM group, this took place at 22-24 hrs. 
 










PET-CT Image Acquisition 
 
A mean administered activity of 244 +/- 6.3 MBq of FLT was injected IV in patients who were well 
hydrated. The PET emission acquisition was started 60 ± 5 minutes after the FLT administration. 
All PET-CT images were acquired on a GE Discovery 710 PET-CT scanner (GE Healthcare, Chicago, 
USA). Patients were positioned in the scanner with their arms raised and each scan covered the 
skull base to the bottom of the liver (covered in 4 to 5 bed positions), with an axial field of view 
of 14.9 cm and an 11- slice overlap. All PET data were acquired in 3D time-of-flight (TOF) 
acquisitions, according to local protocols. A low-dose CT scan (140 kV, 10 mA, 0.5 s rotation time, 
40 mm collimation) was performed at the start in order to provide attenuation correction and 
anatomical localisation. The length of scan was 4 minutes per bed position. The PET data was 
corrected for dead time, scatter, randoms and attenuation using standard algorithms provided 
by the scanner manufacturer. Images were reconstructed using iterative reconstruction with 
time-of-flight (reconstruction parameters: 2 iterations, 24 subsets, Gaussian post filter with 
6.4mm FWHM, 4mm voxels). Both attenuation-corrected and non attenuation-corrected PET 
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images were reconstructed. The response scans were all performed at the same time +/- 5 mins 
after injection as the baseline scan.  
 
PET-CT Imaging Analysis 
 
As there are no guidelines for the use of FLT in response measurement, I used an adaption of the 
EORTC criteria developed for FDG (71). These have previously been used (for FDG) in the ADAM 
trial which investigated arginine deprivation therapy with ADI-PEG20 monotherapy in MPM (40). 
Volumes of interest (VOI)s were drawn manually (TS) using Hermes Gold 3 (Sweden) software 
within the primary tumour at baseline and then subsequent scans.  The maximum standardized 
uptake value (SUVmax) is widely used as a semiquantitative measure of FDG uptake ((107); I note 
that strictly it is per cm3 but it is assumed that soft tissue is equivalent to water, so 1 g/cm3) . 
 
𝑆𝑈𝑉 =  
𝑡𝑟𝑎𝑐𝑒𝑟 𝑢𝑝𝑡𝑎𝑘𝑒 (𝑀𝐵𝑞/𝑚𝐿)
𝑎𝑑𝑚𝑖𝑛𝑖𝑠𝑡𝑒𝑟𝑒𝑑 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦(𝑀𝐵𝑞) / 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑤𝑒𝑖𝑔ℎ𝑡(𝑘𝑔)𝑥1000
 
 
There is no true “gold standard” for evaluating treatment response and in the absence of a 
biochemical parameter, we used the end of treatment diagnostic CT (CT4) as the best surrogate 
to define end of treatment response. As an initial analysis, we compared the PET-CT studies at 
all time points (PET 2, 3 and 4) with this, to assess if the early PET-CT studies were able to predict 
end of treatment response and if FLT PET-CT could be an early biomarker of treatment response. 
 
Treatment response based on percentage change in FLT SUVmax between baseline, early and 
late FLT PET-CT scans was previously published by Scheffler et al. (108), hence we used the 
change in SUVmax from baseline in the analysis of the PET data. A partial response (PR) required 
a 15% reduction in values; progressive disease (PD) was taken to be a 25% increase and stable 
disease (SD) was taken to be everything in between. As a further step, we also looked at all PET 
parameters to see if response on PET2, PET3 and PET4 was concordant with response to 
treatment at CT4.  
 
In a secondary analysis, the effect of scan timepoint was assessed by comparing treatment 
response at an “early” timepoint for PET (change in SUVmax, from baseline, after one cycle of 
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therapy) and CT (change in RECIST length, from baseline after 2 cycles of therapy); and at a “late” 
timepoint, namely end of treatment, namely PET4 and CT4. We looked at effects of timepoint 
(“early”, “EOT”), modality (PET, CT) and patient group (MPM, NSCLC). PET response was 
measured using SUVmax and CT using RECIST length. 
 
As a tertiary analysis of treatment response, we evaluated additional PET parameters, other than 
SUVmax, including SUVmean and SUVpeak as well as maximum, mean and peak SUVs adjusted 
for lean body mass (SULmax, SULmean, SULpeak), to see if these were better markers of 
treatment response compared to SUVmax.   PERCIST measurements (72) were also attempted 
(these use standardized uptake values normalized by lean body mass, so SUL rather than SUV), 
but not used. It was difficult to delineate pleural MPM tumoural uptake adjacent to the ribs on 
FLT PET-CT (as both demonstrate increased tracer uptake); there was high background hepatic 
uptake on FLT PET-CT (in PERCIST criteria, the tumour uptake should be higher than background 
activity); we even attempted to use mediastinal blood pool (MBP) activity (which was low on 
FLT), instead of liver, but again tumour distribution was difficult to assess separate to this, due 
to proximity of tumour in mediastinum.   
We did also attempt to look at survival data (as a surrogate marker of treatment response) and 
plot Kaplan Meier charts looking at progressors and non-progressors as well as responders and 
non-responders. However, as there was only one case in several of the datasets, hence 
unreliable. 
 
Scanner stability and background checks 
 
Scanner stability was assessed using the daily QC phantom SUVmean measurements from 
March 2015 until mid July 2016 (during which time the majority of FLT scans had taken place). 
 
Measurements of background FLT uptake in bone marrow (in the L1 vertebral body) and 
other background regions (liver, mediastinal blood pool and erector spinae muscle) were 
measured by placing regions of interest (ROIs) in these areas over sequential scans. Ratios of 
bone marrow/MBP and bone marrow/liver were also calculated. These provided surrogate data 




2.1.4 Statistical analysis 
 
Statistical analysis was performed using SPSS (IBM SPSS Statistics for Windows, Version 24.0. 
Armonk, NY: IBM Corp). A test for normality (Shapiro-Wilk) showed no significant deviation from 
normality in each PET parameter and so parametric statistical tests were used. 
 
A primary analysis was undertaken using a 2-way repeated measures linear mixed effects ANOVA 
model to look at treatment response at various “time points” on PET scan (PET2, PET3, PET4), 
measured as change in SUVmax from baseline to that timepoint compared to treatment 
response on CT (measured as change in RECIST length from baseline to CT4); and assuming that 
the RECIST change is the gold standard. An additional analysis of the effect of “group” compared 
responses in the MPM and NSCLC groups. Post-hoc pairwise tests were used to further 
investigate significant main effects or interactions. 
 
No statistical analysis was used in assessment of concordance of treatment response using 
EORTC criteria (PR, SD and PD) on PET2, PET 3 and PET4 with CT4.   
 
A secondary analysis looking at the effects of scan timepoint (“early”, “EOT”), modality (PET, CT) 
and patient group (MPM, NSCLC) on change from baseline was investigated using a 3-way 
repeated measures ANOVA executed as a linear mixed effects model using SPSS. Post-hoc 
pairwise tests were used to further investigate significant main effects or interactions. PET 
response was measured using SUVmax and CT using RECIST length. 
 
A tertiary analysis was undertaken again with post-hoc pairwise comparisons in a 3-way repeated 
measures ANOVA model using a linear mixed effect model in SPSS (as with the secondary 
analysis) but this time all 8 PET parameters (SUV measures) were included. 
 
No statistical analysis was used in comparison of treatment response rate on FLT PET-CT using 
EORTC criteria (PR, SD and PD) at PET 2, 3 and 4 and RECIST response on CT after 2 cycles of 






2.2.1 Demographics  
Demographic data is as per Table 3 below.   
 
Table 3 Demographic data in TRAP substudy 
TRAP Demographic data for MPM 
n=10 
 TRAP Demographic data for NSCLC 
n=8 
Age mean (range)/yrs  Age mean (range)/yrs 
all patients 69 (58-82)  all patients 58 (39-65) 
women 69  women 61 (56-64) 
men 69 (58-82)  men 56 (39-65) 
Gender  Gender 
no of female 1  no of female 4 
no of male 9  no of male 4 
ASS1% mean (range)  ASS1% mean (range) 
all patients 79 (51-100)  all patients 82 (55-100) 
women 80  women 81 (55-100) 
men 79 (51-100)  men 82 (70-98) 
 
In the MPM group, there were 5 patients with biphasic MPM; 4 with sarcomatoid MPM, the most 
aggressive subtype (one of which was desmoplastic) and one patient had epithelioid MPM (least 
proliferative).  In the NSCLC group, all were adenocarcinomas (some poorly differentiated). 1.4  
 
In the MPM group, median progression free survival was 5.4 months (range 1.4 – 12.2 months) 
and median overall survival was 11.4 months (range 2.8-23.1 months). In the NSCLC group, 
median progression free survival was 5.2 months (range 2.3 – 10.6 months) and median overall 
survival was 9.0 months (range 2.3-18.8 months).   
 
For radiation exposure calculations - see Appendix B. 
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A primary analysis using a 2-way repeated measures linear mixed effects ANOVA model in the 
combined dataset (all subjects) comparing the treatment response on PET (measured using 
change in SUVmax from baseline to that timepoint) at different timepoints (PET2, PET3 and PET4) 
with response on CT at end of treatment (measured as change in RECIST length from baseline to 
CT4), revealed a significant fixed effect, p <0.001 and hence “real” difference between CT4 and 
PET.  
 
A more detailed analysis using post-hoc pairwise comparison (Table 4) found a mean reduction 
of RECIST length from baseline to CT4 of 21.9%; which is a significantly greater reduction than 
the decrease in SUVmax from baseline to PET2 which was only 2.1%, (p=0.03); and greater than 
the change in SUVmax from  baseline to PET 3 (where SUVmax increased by 3.2%,  p=0.006). 
However, the mean reduction in SUVmax from baseline to PET4 is 36.5% (which is even greater 
than the corresponding reduction on CT) and which is also significantly greater than the decrease 
in SUVmax from baseline to PET2 (2.1%, p<0.001) and baseline to PET 3 (increase of 3.2%, 
p<0.001). Hence treatment response changes at PET4 are not clearly demonstrated at a 
statistically significant level on the earlier PETs (PET2 and PET3). 
 
This ANOVA model also looked for a difference in treatment response between the MPM and 
NSCLC groups, but found no significant difference in response between the groups  (p=0.65).  
























CT4 -21.933 7.075 47.515 -36.163 -7.703 
PET2 -2.103 7.226 48.931 -16.625 12.419 
PET3 3.193 6.933 46.831 -10.756 17.143 




















CT4 PET2 -19.831 8.954 40.58
8 
.032 -37.920 -1.741 
PET3 -25.126 8.618 38.19
4 
.006 -42.570 -7.682 
PET4 14.568 9.234 38.97
2 




PET3 -5.296 8.832 40.06
8 
.552 -23.145 12.553 
PET4 34.399 9.515 41.97
8 
.001 15.197 53.601 
PET4 39.695 9.163 39.34
6 
.000 21.167 58.223 
 
(*) CT4- mean change in RECIST length from baseline to CT4  
PET2, PET3, PET4 – mean change in SUVmax from baseline  
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Concordance of treatment response on PET and CT in terms of PR, SD and PD 
 
As a further step in the initial analysis, we also looked at treatment response in terms of PR, SD 
and PD on PET2, PET3 and PET4 and compared with response to treatment on CT4. For PET, we 
looked at all parameters (not just SUVmax). However, the most reliable PET parameter was found 
to be SUVmax, as it was concordant with CT4 in 62% at PET2 and PET4 (Table 5); demonstrating 
PR, SD or PD in agreement with CT4.  In MPM cases alone, this increased to 71% at PET2, but was 
less concordant with the NSCLC cases (although still 50%).  
 
Table 5. Treatment response on FLT PET-CT in terms of PR, SD and PD concordance with CT4 
 
 All data agreement with 
CT4 
MPM agreement with 
CT4 
NSCLC agreement with 
CT4 














































































































Other PET parameters were less concordant with CT4.  SUL measurements are of uncertain 
significance (FDG does not go into fat and hence can exclude for normalisation, but this may not 




Looking at the data in more depth and subdividing into PR, SD and PD on CT4 (Table 6), we found 
that in cases with PR at CT4, there was good agreement with PET4 as they agreed in 83% cases 
(as also demonstrated on the ANOVA analysis).  Looking at the MPM cases alone, this agreement 
increased to 100% at PET4 (in NSCLC it was 75%). All PET parameters showed a similar response. 
In SD cases, there was good early agreement with 100% agreement with SUVmax at PET2 and 
CT4, suggesting that early FLT PET-CT is as good as CT in predicting stable disease. In PD cases, 
agreement was poor, but there were very few cases.  
 
Table 6 Treatment response on FLT PET-CT in agreement with CT4 divided into PR, SD and PD 
PET2 PET3 PET4 PET2 PET3 PET4 PET2 PET3 PET4
SUVmax 2/6 (33%) 2/7 (29%) 5/6 (83%) 1/2 (50%) 1/3 (33%) 2/2 (100%) 1/4 (25%) 1/4 (25%) 3/4 (75%)
SUVmean 1/6 (17%) 2/7 (29%) 5/6 (83%) 0/2 (0%) 1/3 (33%) 2/2 (100%) 1/4 (25%) 1/4 (25%) 3/4 (75%)
SUVpeak 2/6 (33%) 3/7 (43%) 5/6 (83%) 1/2 (50%) 1/3 (33%) 2/2 (100%) 1/4 (25%) 2/4 (50%) 3/4 (75%)
SULmax 2/6 (33%) 1/7 (14%) 5/6 (83%) 1/2 (50%) 1/3 (33%) 2/2 (100%) 1/4 (25%) 0/4 (0%) 3/4 (75%)
SULmean 2/6 (33%) 2/7 (29%) 5/6 (83%) 1/2 (50%) 1/3 (33%) 2/2 (100%) 1/4 (25%) 1/4 (25%) 3/4 (75%)
SULpeak 2/6 (33%) 2/7 (29%) 5/6 (83%) 1/2 (50%) 1/3 (33%) 2/2 (100%) 1/4 (25%) 1/4 (25%) 3/4 (75%)
PET2 PET3 PET4 PET2 PET3 PET4 PET2 PET3 PET4
SUVmax 5/5 (100%) 5/6 (83%) 3/5 (60%) 3/3 (100%) 2/3 (67%) 2/3 (67%) 2/2 (100%) 3/3 (100%)1/2 (50%)
SUVmean 3/5 (60%) 4/6 (67%) 1/5 (20%) 1/3 (33%) 2/3 (67%) 0/3 (0%) 2/2 (100%) 2/3 (67%) 1/2 (50%)
SUVpeak 4/5 (80%) 3/6 (50%) 2/5 (40%) 2/3 (67%) 1/3 (33%) 1/3 (33%) 2/2 (100%) 2/3 (67%) 1/2 (50%)
SULmax 4/5 (80%) 4/6 (67%) 3/5 (60%) 2/3 (67%) 1/3 (33%) 2/3 (67%) 2/2 (100%) 3/3 (100%)1/2 (50%)
SULmean 3/5 (60%) 4/6 (67%) 1/5 (20%) 2/3 (67%) 2/3 (67%) 0/3 (0%) 1/2 (50%) 2/3 (67%) 1/2 (50%)
SULpeak 4/5 (80%) 3/6 (50%) 2/5 (40%) 2/3 (67%) 1/3 (33%) 1/3 (33%) 2/2 (100%) 2/3 (67%) 1/2 (50%)
no PD NSCLC
PET2 PET3 PET4 PET2 PET3 PET4
SUVmax 1/2 (50%) 0/3 (0%) 0/2 (0%) 1/2 (50%) 0/3 (0%) 0/2 (0%)
SUVmean 0/2 (0%) 0/3 (0%) 0/2 (0%) 0/2 (0%) 0/3 (0%) 0/2 (0%)
SUVpeak 0/2 (0%) 1/3 (33%) 0/2 (0%) 0/2 (0%) 1/3 (33%) 0/2 (0%)
SULmax 1/2 (50%) 0/3 (0%) 0/2 (0%) 1/2 (50%) 0/3 (0%) 0/2 (0%)
SULmean 0/2 (0%) 0/3 (0%) 0/2 (0%) 0/2 (0%) 0/3 (0%) 0/2 (0%)
SULpeak 0/2 (0%) 0/3 (0%) 0/2 (0%) 0/2 (0%) 0/3 (0%) 0/2 (0%)
PD at CT4 (all) PD at CT4 (MPM only)
PR at CT4 (all) PR at CT4 (MPM only) PR at CT4 (NSCLC only) 
SD at CT4 (all) SD at CT4 (MPM only) SD at CT4 (NSCLC only) 
 
 
In terms of clinical outcomes in treatment response, it is important to know if the patient is 
progressing on treatment (so that it can be changed), hence progression and non-progression 
dichotomy is important for clinical management decisions. Therefore, we also grouped together 
the non-progressors (NP=PR+SD) and reanalysed (Table 7).  In MPM non progressors, FLT 
SUVmax at PET 2 and PET 4 is concordant with CT4 in 80%; in NSCLC PET 4 is concordant with 
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CT4 in 67%, suggesting that in MPM, early FLT PET can predict early response to treatment better 
than in NSCLC.  
 
Table 7. Response on FLT PET-CT agreement with CT4 in PD and non-progressors (NP= SD+PR) 
NP at CT4 NP at CT4 (MPM only) NP at CT4 (NSCLC only) 
PET2 PET3 PET4 scan2 scan3 scan4 scan2 scan3 scan4
SUVmax 7/11 (64%) 6/13 (46%) 8/11 (72%) 4/5 (80%) 3/6 (50%)4/5 (80%) 3/6 (50%) 4/7 (57%) 4/6 (67%)
SUVmean 4/11 (36%) 6/13 (46%) 6/11 (55%) 1/5 (20%) 3/6 (50%)2/5 (40%) 3/6 (50%) 3/7 (43%) 4/6 (67%)
SUVpeak 6/11 (55%) 6/13 (46%) 7/11 (64%) 3/5 (60%) 2/6 (33%)3/5 (60%) 3/6 (50%) 4/7 (57%) 4/6 (67%)
SULmax 6/11 (55%) 5/13 (38%) 8/11 (73%) 3/5 (60%) 2/6 (33%)4/5 (80%) 3/6 (50%) 3/7 (43%) 4/6 (67%)
SULmean 5/11 (45%) 5/13 (38%) 6/11 (55%) 3/5 (60%) 3/6 (50%)2/5 (40%) 2/6 (33%) 2/7 (29%) 4/6 (67%)
SULpeak 6/11 (55%) 5/13 (38%) 7/11 (64%) 3/5 (60%) 2/6 (33%)3/5 (60%) 2/6 (33%) 3/7 (43%) 4/6 (67%)
PD at CT4 PD at CT4 (MPM only) no PD NSCLC
scan2 scan3 scan4 scan2 scan3 scan4
SUVmax 1/2 (50%) 0/3 (0%) 0/2 (0%) 1/2 (50%) 0/3 (0%) 0/2 (0%)
SUVmean 0/2 (0%) 0/3 (0%) 0/2 (0%) 0/2 (0%) 0/3 (0%) 0/3 (0%)
SUVpeak 0/2 (0%) 1/3 (33%) 0/2 (0%) 0/2 (0%) 1/3 (33%)0/2 (0%)
SULmax 1/2 (50%) 0/3 (0%) 0/2 (0%) 1/2 (50%) 0/3 (0%) 0/2 (0%)
SULmean 0/2 (0%) 0/3 (0%) 0/2 (0%) 0/2 (0%) 0/3 (0%) 0/2 (0%)
SULpeak 0/2 (0%) 0/3 (0%) 0/2 (0%) 0/2 (0%) 0/3 (0%) 0/2 (0%)
 
 
In phase 1 trials, subdividing into responders and non-responders (NR=SD+PD) (Table 8) is a more 
relevant dichotomisation, as here you are looking for drug effect. In non-responders, PET 2 is 
concordant with CT4 in 86% overall, in 80% MPM and all NSCLC cases. In responders, PET 4 is 
concordant with CT4 in 83% overall, in all MPM cases and in 75% of responders NSCLC. However, 





Table 8. Response on FLT PET-CT agreement with CT4 in PR and non responders (NR= SD + PD) 
PR at CT4 PR at CT4 (MPM only) PR at CT4 (NSCLC only) 
scan2 scan3 scan4 scan2 scan3 scan4 scan2 scan3 scan4
SUVmax 2/6 (33%) 2/7 (29%) 5/6 (83%) 1/2 (50%)1/3 (33%)2/2 (100%) 1/4 (25%) 1/4 (25%) 3/4 (75%)
SUVmean 1/6 (17%) 2/7 (29%) 5/6 (83%) 0/2 (0%) 1/3 (33%)2/2 (100%) 1/4 (25%) 1/4 (25%) 3/4 (75%)
SUVpeak 2/6 (33%) 3/7 (43%) 5/6 (83%) 1/2 (50%)1/3 (33%)2/2 (100%) 1/4 (25%) 2/4 (50%) 3/4 (75%)
SULmax 2/6 (33%) 1/7 (14%) 5/6 (83%) 1/2 (50%)1/3 (33%)2/2 (100%) 1/4 (25%) 0/4 (0%) 3/4 (75%)
SULmean 2/6 (33%) 2/7 (29%) 5/6 (83%) 1/2 (50%)1/3 (33%)2/2 (100%) 1/4 (25%) 1/4 (25%) 3/4 (75%)
SULpeak 2/6 (33%) 2/7 (29%) 5/6 (83%) 1/2 (50%)1/3 (33%)2/2 (100%) 1/4 (25%) 1/4 (25%) 3/4 (75%)
NR at CT4 NR at CT4 (MPM only) NR at CT4 (NSCLC only) 
scan2 scan3 scan4 scan2 scan3 scan4 scan2 scan3 scan4
SUVmax 6/7 (86%) 5/9 (56%) 3/7 (43%) 4/5 (80%)2/6 (33%)2/5 (40%) 2/2 (100%) 3/3 (100%) 1/2 (50%)
SUVmean 3/7 (43%) 4/9 (44%) 1/7 (14%) 1/5 (20%)2/6 (33%)0/5 (0%) 2/2 (100%) 2/3 (67%) 1/2 (50%)
SUVpeak 4/7 (57%) 4/9 (44%) 2/7 (29%) 2/5 (40%)2/6 (33%)1/5 (20%) 2/2 (100%) 2/3 (67%) 1/2 (50%)
SULmax 5/7 (71%) 4/9 (44%) 3/7 (43%) 3/5 (60%)1/6 (17%)2/5 (40%) 2/2 (100%) 3/3 (100%) 1/2 (50%)
SULmean 6/7 (86%) 5/9 (56%) 3/7 (43%) 4/5 (80%)2/6 (33%)2/5 (40%) 2/2 (100%) 3/3 (100%) 1/2 (50%)




To summarise this section, ANOVA analysis reveals that in the combined dataset (all subjects), 
response to treatment demonstrated on CT4 in terms of change from baseline (21.9% decrease 
in RECIST length), is also seen in PET4 and the change is even greater on PET (mean decrease of 
36.5% in SUVmax); however, these treatment response changes are not clearly demonstrated at 
a statistically significant level on the earlier PETs.  
However, FLT SUVmax treatment response on early PET (PET2) in terms of PR, SD and PD can 
predict end of treatment response on RECIST (using CT4 as gold standard) in more than 50% of 
cases (62% cases overall) and better in MPM (71%) than NSCLC (50%). In cases of PR, there was 









The initial analysis assumed CT4 as the “gold standard” in the comparison of ADIPEMCIS 
treatment response on PET and CT. However, as there is no imaging gold standard, we 
considered other endpoints such as overall survival (OS) and progression free survival (PFS); 
unfortunately, the sample size was considered too small. Therefore, as a secondary analysis, we 
looked at the concordance and discordance of the PET and CT data at different timepoints, 
namely “early” (PET 3 and CT2) and “end of treatment (EOT)” or “late” (PET4 and CT4), under the 
hypothesis that decreased proliferation is highly suggestive of drug effect and precedes any 
change in size. PET3 and CT2 were at slightly different timepoints (PET3 after one cycle of 
treatment, with CT2 after 2 cycles).  PET4 and CT4 were both at the end of treatment, at 
approximately 18 weeks for MPM and 12 weeks for NSCLC. 
 
This secondary analysis ANOVA assumes the data is normally distributed so this assumption was 
explored using the Shapiro-Wilks test and no significant deviation from normality was found. 
 
The 3-way ANOVA results showing main effects of time, modality and group and their 2-way and 
3-way interactions is shown in Table 9. 
 
Table 9. Summary ANOVA table 
Effect F ratio Significance 
Time 14.804 < 0.001 
Group .011 .918 
Modality .130 .720 
Time * Group .116 .736 
Time * Modality 7.530 .009 
Group * Modality 11.088 .002 
Time * Group * Modality .111 .740 
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Effect of Time 
 
Significant main effects were only revealed for time (p<0.001), with EOT having a larger negative 
change (reduction in value) than early scans: -28.2% compared to -5.5% respectively (see Table 
10). The estimated confidence intervals suggest the EOT scans showed a real change while the 
early scans did not.  
Hence the primary observation from this analysis is that the EOT scan time point revealed a 
significantly negative change, which was not observed in (and was significantly different to) the 
early time point. 
 
Table 10. Post-hoc means & differences between time points in all patients (18 total; 10 MPM 
















Early -5.503 5.926 23.22
9 
-17.754 6.749 















Early EOT 22.654 5.888 41.436 <0.001 10.767 34.540 
 
(*) Early- mean change in RECIST length from baseline to CT2 and SUVmax from baseline to PET3; 




2-way Interaction between Time and Modality 
 
A significant 2-way interaction was found between time and modality (p = 0.009). Table 11 shows 
the estimated means and differences between time & modality. This interaction effect appears 
to be driven by a difference between the modality only in the early scans with CT2 showing a 
significantly greater change than PET3 (-14.6% vs 3.6%, p = 0.026).  
Hence CT scans appear to show a significant decrease at the early scan which is not observable 
in the PET scan, therefore, a decrease in size (RECIST length) appears to precede a decrease in 
proliferation (SUVmax), which does not support our hypothesis. However, it is important to note 
that PET3 at 2 weeks (after one cycle), preceded CT2 (after 2 cycles) by 3 weeks and it is possible 
that the changes on CT may not have been observed if the early CT had been performed at the 
earlier PET 3 time-point, namely at 2 weeks. 
 
At the EOT timepoint, post hoc analysis revealed a significant decrease in both CT and PET 





Table 11. Post-hoc means & differences of time and modality (p=0.009) 
 
Estimates 
Time Modality Mean 
Change 












Early CT2 -14.588 6.998 38.90
3 
-28.743 -.433 
PET3 3.582 7.227 40.57
6 
-11.017 18.182 
EOT CT4 -21.182 7.355 41.75
7 
-36.027 -6.337 















Early CT2 PET3 -18.170* 7.869 40.96
8 
.026 -34.063 -2.277 
EOT CT4 PET4 13.949 8.665 40.74
6 
.115 -3.553 31.450 
 
(*) Early CT2- mean change in RECIST length from baseline to CT2; 
Early PET3- mean change in SUVmax from baseline to PET3; 
EOT CT4- mean change in RECIST length from baseline to CT4;  





2-way Interaction between Group and Modality 
 
A significant 2-way interaction was found between and group and modality (p = 0.002). 
Table 12 shows the estimated means & differences between group & modality. Here, it appears 
in the MPM group, PET scans show a significant decrease in proliferation compared to CT (-26.1% 
vs -8.7% respectively, p = 0.031). Conversely, in the NSCLC group change in CT measures were 
more negative than PET (-27.1% vs -5.5%, p = 0.018). The significant interaction of modality and 
group appears to be driven by changes in PET measures in the MDM group, and conversely by 
CT measures in the NSCLC group.  
 
Table 12. Post-hoc means & differences of group and modality (p=0.002) 
Estimates 
Group Modality Mean 
Change in 
Modality 
Measure (*)  
Std. 
Error 





MPM CT -8.704 7.927 23.590 -25.080 7.671 
SUVmax -26.081 8.240 26.580 -43.001 -9.162 
NSCLC CT -27.066 8.915 23.765 -45.475 -8.656 





















CT SUVmax 17.377* 7.753 40.506 .031 1.714 33.040 
CT SUVmax -21.599* 8.769 41.113 .018 -39.307 -3.891 
(*) CT modality measure is RECIST length; PET modality measure is SUVmax 
 
Despite the overlap of main effects in 2-way interactions, 3-way interactions were not observed 
to be significant and a strong consistent message across the board is less obvious. The higher p-
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values in the post-hoc pairwise comparisons may not survive stricter multiple comparison 
corrections and reflect this. 
 
Correlation of PET parameters  
 
In a tertiary analysis, the 3-way ANOVA model was repeated using a linear mixed effect model in 
SPSS as with the secondary analysis, however all 8 SUV measures were included. Not surprisingly, 
the SUV measures all show strong (r > 0.8) and highly significant (p < 0.001) correlation 
coefficients with each other (Table 13). 
 
Table 13. Percentage change in all PET parameters 
 
   Overall response on PET
PR SD PD 
PET2 PET3 PET4 PET2 PET3 PET4 PET2 PET3 PET4
SUV max 20% 24% 69% 67% 65% 31% 13% 12% 0%
SUV mean 13% 18% 77% 73% 65% 15% 13% 18% 8%
SUV peak 20% 35% 77% 73% 35% 23% 7% 29% 0%
SUL max 20% 18% 69% 67% 65% 31% 13% 18% 0%
SUL mean 20% 12% 77% 67% 71% 15% 13% 18% 8%
SUL peak 20% 29% 77% 20% 29% 77% 7% 29% 0%
   MPM response on PET
PR SD PD 
PET2 PET3 PET4 PET2 PET3 PET4 PET2 PET3 PET4
SUV max 25% 30% 71% 63% 60% 29% 13% 10% 0%
SUV mean 13% 20% 86% 63% 70% 0% 25% 10% 14%
SUV peak 25% 40% 86% 63% 30% 14% 13% 30% 0%
SUL max 25% 30% 71% 50% 50% 29% 25% 20% 0%
SUL mean 13% 20% 86% 63% 70% 0% 25% 10% 14%
SUL peak 25% 40% 86% 63% 30% 14% 13% 30% 0%
   NSCLC response on PET
PR SD PD 
PET2 PET3 PET4 PET2 PET3 PET4 PET2 PET3 PET4
SUV max 14% 14% 67% 71% 71% 33% 14% 14% 0%
SUV mean 14% 14% 67% 86% 57% 33% 0% 29% 0%
SUV peak 14% 29% 67% 86% 43% 33% 0% 29% 0%
SUL max 14% 0% 67% 86% 86% 33% 0% 14% 0%
SUL mean 29% 0% 67% 71% 71% 33% 0% 29% 0%





2.2.4 Response rate assessment on PET and CT  
 
A change in SUVmax from baseline was used to assess treatment response on FLT PET-CT using 
EORTC criteria for PR, SD and PD at timepoints PET2,3 and 4; and this was compared to RECIST 
response on CT at the same/similar timepoints(CT3 after 2 cycles and CT4 at EOT). 
 
In patients with MPM (all subtypes included), the PR rate (number of subjects demonstrating PR 
out of total number of subjects with PET scan at that particular time-point) was 25% at PET2; 
increased to 30% at PET3 and increased further to 71% at PET4 (Table 14, Figures 11, 17, 18). The 
PR rate on CT was lower at 33% at the end of treatment (Figure 12). This is in line with the ANOVA 
result above.   
 
Table 14. MPM: Response on FLT PET-CT and CT 
 
    MPM response on PET   MPM response on CT 
  PET2 PET3 PET4 
  







































Figure 11. MPM response on FLT PET-CT in n=10 patients 
 
 








In NSCLC subjects, the PR rate on PET was 14% at PET2 and PET3, but increased to 67 % at PET4 
(Table 15, Figure 13). The PR rate on CT was slightly lower at 57% at the end of treatment (Figure 
14). 
  
Table 15. NSCLC: Response on FLT PET-CT and CT 
    NSCLC response on PET   NSCLC response on CT 






































total 7 7 6     8 7 
 
 





Figure 14. NSCLC response on CT in n=8 patients 
 
 
When considering combined MPM and NSCLC data, the PR rate overall was 20% at PET2; 
increased to 24% at PET3 and increased again to 69% at PET4 (Table 16, Figure 15). The PR rate 
on CT was lower at 44% at the end of treatment (Figure 16). The early CT (at approximately 5 
weeks), demonstrates stable disease in the majority of cases in all groups, namely 70%, 75% and 
73% in MPM, NSCLC and combined data, respectively.  
 
Table 16. Combined (MPM+ NSCLC): Response on FLT PET-CT and CT 
    Overall response on PET   Overall response on CT 
  PET2  PET3 PET4 
  


































total 15 17 13     18 16 
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Figure 15. Combined data response on FLT PET-CT in n=18 patients 
 
 




FLT PET-CT proliferation imaging showed greater treatment response to ADIPEMCIS therapy than 




Figure 17. FLT PET-CT in epithelioid MPM 
a) baseline SUVmax = 9.4; (b) post ADI-PEG20 at 24hrs, the SUVmax reduces to 8.9 (5% reduction 
hence SD); (c) post cycle 1 of combined therapy, the SUVmax decreases further to 7.7 (18% 
reduction from baseline hence PR); however at (d) end of treatment, the SUVmax increases 
minimally to 8.5 (10% reduction from baseline hence SD).  CT also showed overall SD at end of 
treatment (although at this slice visually there appears to be a PR, the average of 3 






















Figure 18. FLT PET-CT in biphasic MPM 
a) baseline SUVmax=6.4; (b) post ADI-PEG20 at 24hrs, the SUVmax reduces to 5.9 (8% reduction 
hence SD); (c) post cycle 1 of combined therapy, the SUVmax increased minimally to 6.2 
(maintained SD); however at (d) end of treatment, the SUVmax decreases significantly to 1.0 
(84% reduction from baseline hence PR).  CT overall showed SD (although again visually there 
appears to be PR at this slice, an average of 3 measurements revealed a 10% decrease in RECIST 


























Figure 19. FLT PET-CT in NSCLC 
(a) baseline where primary lesion has SUVmax=6.4; (b) post ADI-PEG20 at 24hrs, the SUVmax 
reduces to 4.8 (25% reduction hence PR); (c) post cycle 1 of combined therapy, the SUVmax 
increases slightly to 5.4; however at (d) end of treatment, the SUVmax decreases further to 4.1 
(36% reduction from baseline) and hence PR is maintained.  CT also shows a PR at end of 


























2.2.5 Summary of results 
 
The main findings from our study are: 
 
ANOVA analysis (using CT4 as the gold standard) revealed that response to treatment was 
greater on PET4 (mean decrease of 36.5% in SUVmax), than CT4 (21.9% decrease in RECIST 
length); however, these response changes are not clearly demonstrated on the earlier PETs. 
 
FLT PET-CT SUVmax treatment response at PET2 in terms of PR, SD and PD can predict end of 
treatment response on RECIST (using CT4 as gold standard) in nearly 2/3 of cases (62% cases 
overall) and better in MPM (71%) than NSCLC (50%), however the SUVmax reduction from 
baseline to PET2 is not statistically significant and there is no difference between the MPM and 
NSCLC groups.  
 
In cases of PR, there is good agreement in PET4 with CT4 with (83% overall, 100% in MPM and 
75% in NSCLC); and no significant difference between CT and SUVmax at the end of treatment. 
 
At the early imaging time point (post 1 cycle on PET3 and 2 cycles on CT), there is a statistically 
significant difference (p =0.026) in the way CT and SUVmax measures behave, with the greater 
decrease seen in RECIST length on CT than SUVmax on PET. At the EOT timepoint, there is a 
significant decrease in both CT and PET measures, but no statistically difference between 
modalities (p=0.115). Hence changes in proliferation do not precede changes in size, as at no 
earlier timepoint is there are a significant difference between RECIST length and SUVmax 
reduction. The MPM group shows predominantly decrease in SUVmax (26%, p=0.031) whereas 
the NSCLC group show decrease mainly in RECIST length (27%, p=0.018), irrespective of time. 
 
All PET parameters show strong correlation (r >0.8) which is highly significant (p < 0.001). 
SUVmax was the most reliable, as it was concordant with CT4 in 62% at PET2 and PET4.  
 
FLT PET-CT proliferation imaging showed greater treatment response to ADIPEMCIS therapy than 





TRAP was the first study in humans of FLT PET evaluating the response of MPM and NSCLC to 
systemic treatment using arginine deprivation with ADI-PEG20 alone and in combination with 
chemotherapy.  
 
This study shows that FLT PET is at least as good as CT in demonstrating treatment response, at 
end of treatment. FLT is known to be a biomarker of cellular proliferation and advantages of FLT 
over FDG in monitoring treatment response have been described. Buck et al. assessed the 
correlation between FLT uptake and lung tumour proliferation and concluded FLT uptake 
correlated well with Ki-67 staining in malignant primary lung tumours (88). Other studies in lung 
cancer have shown conflicting results on the relationship between Ki-67 and FLT uptake, with 
some studies confirming a good correlation and others presenting negative results.  A study 
looking at change in FLT SUVmax between baseline and 7 days after the start of gefitinib therapy 
in patients with adenocarcinoma of the lung found that responders (as defined on CT evaluation 
at 6 weeks) had a significantly different change in SUVmax than non-responders (−36.0 ± 15.4% 
versus 10.1 ± 19.5%, respectively; p < 0.001)(91).  
 
We did not directly compare FDG and FLT PET in this study, however, this has been evaluated in 
other studies. In one study in NSCLC patients who underwent EGFR kinase inhibitor treatment 
found that change in FDG SULpeak from baseline to 3 weeks post-treatment was significantly 
better than change in FLT SULpeak at predicting overall survival and progression-free survival 
(109). Interestingly, Everitt et al. evaluated differential FDG and FLT uptake on serial PET-CT 
imaging before and during definitive chemoradiation for NSCLC and found that FLT PET-CT was 
a more sensitive tracer of early treatment response (weeks 2 and 4) than FDG PET-CT (110). Tian 
et al. (90), found that in 55 patients with pulmonary nodules who underwent FDG and FLT PET 
within 7 days, the sensitivity and specificity for FDG was 87.5% and 58.9% and 68.7% and 76.9% 
for FLT. The combination of the two improved sensitivity to 100% and specificity to 89.7%. 
 
We found that a very early scan at 24 hours after ADI therapy is able to predict end of treatment 
RECIST response in 62% of cases.  In a study looking at FLT PET-CT in pemetrexed therapy in 
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NSCLC, a non-systematic reduction in FLT uptake was observed 4 hours after pemetrexed 
administration. However, the association between FLT uptake and treatment response was not 
significant (111).  A very recent publication, looking at early response assessment to targeted 
therapy using FLT in lung cancer, showed early response demonstrated at 4 weeks and in one 
case at 9 days (112). 
 
We evaluated multiple PET parameters, including maximum standard uptake value adjusted for 
lean body mass, SULmax, as this had been evaluated in a prior study by Crandall et al. (82) and is 
consistent with PERCIST criteria evaluation. We found good correlation between all parameters 
(r >0.8, p <0.001), but used SUVmax in the majority of our study as this parameter showed most 
consistent overall agreement with end of treatment CT and can predict end of treatment 
response (on RECIST) in more than 50% of cases (62% cases overall) although better in MPM 
(71%) than NSCLC (50%).    
 
Crandall had looked at percentage change in FLT and FDG uptake (as measured by SULmax,) 
between baseline and after one cycle of chemotherapy in NSCLC patients categorised by RECIST 
1.1 CT as responders or non-responders after two cycles of therapy (docetaxel + cisplatin). Post 
cycle one, non-responders had mean SULmax increases of 7.0 and 3.4% for FDG and FLT, 
respectively. Responders had mean decreases of 44.8 and 32.0% in FDG and FLT SULmax, 
respectively. Post cycle one, primary tumour FDG SUL values were significantly lower in 
responders than in non-responders (P = 0.016), but primary tumour FLT SUL values did not differ 
significantly between these groups. The study concluded that fractional decrease in FDG SULmax 
from baseline to post-cycle 1 imaging was significantly different between anatomic responders 
and non-responders (also seen in the ADAM study, but using SUVmax), while percentage changes 
in FLT SULmax were not significantly different between these groups over the same period of 
time. PERCIST measurements on FLT PET-CT use SUL parameters, however, although we 
attempted to use these, we found it difficult to accurately delineate pleural MPM tumoural 
uptake (as explained in “methods” section); hence, we did not use PERCIST criteria. 
 
Our hypothesis does not hold as a decrease in proliferation does not seem to precede a change 
in size. Nevertheless, treatment response was correctly predicted at 24 hours in 62% cases. Also, 
it is important to note that the “early” PET at 2 weeks, preceded the “early” CT by 2-3 weeks and 
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it is possible that the changes on CT may not have been observed if the early CT had been 
performed at an earlier time-point, namely at 2 weeks.  Early phase combination trials of ADI-
PEG20 with chemotherapy are reporting increased efficacy, and sustained arginine depletion 
with reduced immunogenicity of ADI-PEG 20 (42). In thoracic cancers this multimodality strategy 
has instigated the phase 2/3 ATOMIC-meso trial of pemetrexed and cisplatin with or without 
ADI-PEG 20 focusing on chemorefractory (non-epithelioid) MPMs.  
 
Recent and as yet unpublished work by Szlosarek et al from an expansion group of the TRAP 
study of n=31 participants (primarily looking at safety and resistance) showed disease control 
rate of 93.5% and partial response 35.5% at 18 weeks. Post ADI therapy biopsies from 6 
participants who had progressed showed that there were 4 mechanisms of resistance, which 
could help explain our findings. Firstly there was patchy tumoural re-expression of ASS1 (thus 
recycling of citrulline to arginine); autophagy (degradation and recycling of cellular components; 
increased tumour associated macrophages which were significant (p=0.02) in ASS1 tumour 
areas; and changes in the tumour microenvironment, including increased tumoural  programmed 







We do not have FLT test retest data in this study, but we have assumed that this is similar to 
published literature (113) (test-retest r ≥ 0.97 on serial baseline scans in a study on breast 
cancer).  
A major limitation of our study is that there is no biochemical marker to act as the gold standard 
and we are relying on RECIST data, as there was no better surrogate marker of response 
available. However, RECIST response looks at changes in size, whereas FLT PET-CT looks at 
changes in proliferation. The number of patients is also too small to reliably compare to OS or 
PFS. 
These patients are typically unwell symptomatically due to the significant burden of disease and 
thus difficult to recruit. This was a longitudinal study and a number of patients were unable to 
complete the full imaging protocol due to morbidity. Tracer production and quality control was 
also an issue and the availability of tracer only once a week meant that there was little flexibility.  
A change in day of production of tracer halfway through the study meant that the patients were 
needing ADI-PEG20 administration on a Sunday. Also, the cohorts for EORTC and RECIST 




The TRAP substudy shows that early FLT PET-CT (at 24 hours post ADI therapy) is predictive of 
the end of treatment CT results in nearly 2/3 cases and FLT PET-CT does provide evidence of 
response to ADI therapy in ASS1-deficient thoracic tumours which appears higher than the 
RECIST 1.1 response rate at the end of treatment. This study therefore provides molecular 
validation for arginine deprivation with ADI-PEG20 in targeting thymidine uptake as a treatment 
for ASS1-deficient thoracic tumours, however, decrease in proliferation does not seem to 









ADAM was a phase 2 clinical trial (NCT01279967) of ADI-PEG 20 and best supportive care vs best 
supportive care alone in patients with malignant pleural mesothelioma (ADAM). Written 
informed consent for each patient and ethical approval for the study was obtained 
(09/H1102/107) as well as approvals from MHRA and ARSAC. I was a co-Investigator in this study 
responsible for supervising and overseeing the PET studies, ensuring the PET studies were 
performed in accordance with the protocol and good clinical practice (GCP). I also was the central 




From March 2011 to June 2013, 86 patients at 6 centres, with histologically proven advanced 
ASS1-deficient MPM (defined as >50% ASS1 loss) and measurable disease by modified Response 
Evaluation Criteria in Solid Tumours (RECIST) criteria were recruited into the phase 2 randomised, 
non-blinded trial to receive a weekly intramuscular injection of ADI-PEG20 (36.8 mg/m2) for up 
to 6 months (cycles) into the buttock plus best supportive care (BSC), or BSC alone. 
Randomization was performed at a Trials Centre, where a computer program allocated patients 
to the respective arms of the study. In our substudy, we analysed textural features in 20 patients 




Inclusion criteria included life expectancy of at least 3 months, over 18 years of age, Eastern 
Cooperative Oncology Group (ECOG) performance status (PS) 0-1 with adequate haematological, 





Patients with surgically resectable disease, recurrent pleural effusion (not pleurodesed), receipt 
of extensive radiation (hemi-thorax) therapy within 6 weeks before enrolment, brain and spinal 
cord metastases, uncontrolled or severe heart disease, pregnancy, seizures and allergy to 





3.1.2 Imaging and Analysis 
 
Computed Tomography (CT) 
 
CT imaging was performed as part of routine clinical care and performed at baseline and at the 
end of month 2, 4, 6 and end of treatment. Progression free survival (PFS) and overall survival 
(OS) were also recorded. 
 
CT Image Acquisition 
 
Diagnostic CTs were acquired as standard of care on a Definition AS 64 slice CT scanner (Siemens 
Healthcare, Erlangen, Germany) at St. Bartholomew’s Hospital. IV contrast-enhanced CT scans 
obtained with a minimum slice thickness of 3–5 mm were available for review. Each patient 
received 80–100 mL of IV iodinated contrast medium (iodixanol 300 or iohexol 300) injected at 
a rate of 2–3 mL/s, and scanning began after a delay of 20-25 seconds for arterial and 75–90 
seconds after injection for the portovenous phase imaging. 
 
CT Image Analysis 
 
CT response was assessed by an experienced radiology (SE) at St Bartholomew’s hospital using 
modified RECIST (MPM) criteria (Byrne et al). Uni-dimensional measurements of tumour 
thickness perpendicular to the chest wall were measured at 2 sites at 3 different levels on CT 
scan, at least 1 cm apart. At reassessment, pleural thickness was measured at the same position 
and level. Nodes were not measured.  Uni-dimensional measurements are added to produce the 
total tumour measurement, so the sum of 6 pleural thickness measurements = one univariate 
diameter. Complete response (CR) was defined as the disappearance of all target lesions with no 
evidence of tumour elsewhere, and PR was defined as at least a 30% reduction in the total 
tumour measurement. Progressive disease (PD) was defined as an increase of at least 20% in the 
total tumour measurement over the nadir (lowest) measurement, or the appearance of one or 
more new lesions. Patients with stable disease (SD) were those who fulfilled the criteria for 






As part of the translational component of this study, patients receiving ADI-PEG 20 underwent a 
FDG PET-CT scan at baseline and at approximately 4 weeks. A subset of 20 patients who had 
received ADI-PEG 20 treatment at a single institution (St. Bartholomew’s Hospital, Barts) had 
textural features of the FDG PET data analysed. The low dose CT was not assessed as tumour 
delineation was suboptimal and prior studies have assessed texture features using diagnostic CT. 
 
PET-CT Imaging Acquisition 
 
The subset of patients from Barts were injected with 347 (+/-20) MBq FDG. All patients fasted 
for 6 h and the uptake time was 60 min. All data were acquired on a Philips Gemini TF LSO64 
system with 3-dimensional time-of-flight (TOF) PET scanner together with a 16-slice Brilliance CT 
scanner (Philips Healthcare, Best, the Netherlands). Patients were imaged supine from skull base 
to upper thighs with arms raised above head to avoid attenuation artefacts. A low dose CT scan 
was acquired first (parameters: 40 mAs, 140 kV, 0.5 s per tube rotation) with a slice thickness of 
5 mm, a scan length of approximately 900mm and data acquisition time of 22.5 s. The CT scan 
was acquired during free breathing. This was immediately followed by PET acquisition with a 3 
min per bed position (6–7 bed positions) and 7-slice overlap in 3D reconstruction mode (matrix 
size 128×128). The acquisition time was approximately 30–40 min. The CT data were used for 
attenuation correction and localization. Iterative reconstruction with ordered-subset 
expectation maximisation (OSEM)(ordered subset expectation maximisation; 33 subsets, three 





PET-CT Image Analysis 
 
Images were transferred to a HERMES workstation (Hermes Medical Solution, London, UK) for 
reporting.  Volumes of interest (VOIs) of the primary tumour on FDG PET images were manually 
selected. Nodal disease was not included in this analysis. 
 
Calculation of the textural features was performed by using in-house software implemented with 
MATLAB (MathWorks, Natick, Massachusetts). Voxel values within the tumour VOI were 
resampled to yield 64 discrete bins. A selection of parameters were chosen, as detailed in Table 
1 (introduction). These specific parameters were chosen as they had been examined in a 






3.1.3 Statistical analysis 
 
Statistical analyses were performed by an experienced statistician (P.B).  
Changes in features with treatment from baseline to 4 weeks were assessed using a one sample 
t-test (as data followed a normal distribution (except for uniformity, coarseness, TLG and 
kurtosis). Associations of texture features with treatment response based on modified RECIST 
response (at 2 months) and PFS and OS were assessed using Cox regression models. Associations 
of texture features with metabolic tumour volume were assessed using Pearson correlation. 
 
Analyses were performed for the texture variables at baseline, 4 weeks post treatment and also 
for the percentage change in values from baseline to 4 weeks, except in skewness and kurtosis, 
where the raw change in scores was examined.  
 
Tumour response to ADI- PEG 20 was defined according to the modified RECIST criteria by an 
independent radiologist (S.E) who was blinded to the PET results. Patients were then 
dichotomized into progressors (PD) and non-progressors (SD, PR and CR) on the basis of these 
criteria. Response according to contrast-enhanced CT findings was used in preference to a PET-
based response to provide a measurement independent of the PET studies.  
 
The analyses were performed in two stages. Firstly, the separate association between each 
variable and each outcome was examined separately in a series of univariable analyses.   
The second stage of the analysis examined the joint association of the variables in a multivariable 
analysis.  Before this stage of the analysis, the collinearity between the texture variables was 
examined using variance inflation factors (which occurs when two, or more, factors are strongly 
associated with each other). To avoid potential problems in regression analysis where collinearity 
was detected, one of the variables was excluded from the multivariable analyses. A backwards 
selection was performed to retain only the significant variables in the final mode (omitting non-
significant variables, one at a time, until all remaining variables are significant).  Apart from the 






3.2.1 Demographics  
 
There were 20 patients in this dataset; 17 of whom were male (Table 17). They were all non 
sarcomatoid mesothelioma (MPM) cases on histology and ASS1 levels were above 50%.   
 
Table 17. Demographic data in subset of ADAM study (n=20) 
Age mean (range) /yrs 
all patients 64 (54-77) 
Women 62 (59-67) 
Men 65 (54-77) 
Gender 
no of female 3 
no of male 17 
Histology  
no of MPM sarcomatoid 0 
no of MPM non sarcomatoid 20 
ASS1% 
all patients 64 (50-100) 
Women 53 (50-60) 
 
The actual post ADI therapy FDG PET-CT scans were performed after a mean of 23 days (+/- 6.2) 
and hence slightly earlier than 4 weeks. RECIST measurements were performed on diagnostic 
CTs at 2 months post therapy.  
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3.2.2 Changes with treatment from baseline to 4 weeks 
 
Baseline, 4-week values and percentage change for all measured parameters are summarised in 
Table 18. Most data values were normally distributed and hence were summarised by the mean 
and standard deviation (SD).  Uniformity, coarseness, TLG and kurtosis were not normally 
distributed and hence median and inter-quartile ranges were used. The fourth column shows the 
mean percentage change between time points, along with a corresponding confidence interval. 
The exception is for two parameters (skewness and kurtosis) where the absolute change was 
preferred, when again the average change is shown with a corresponding confidence interval.  
 
Table 18. Baseline, 4-week values and percentage change for all measured parameters 
Parameter 
 
Baseline 4 weeks % change 
Mean (95% CI) 
P-value 
SUVmax 8.5 ± 2.5 8.0 ± 2.5 -6 (-12, 0) 0.05 
SUVmean 3.3 ± 1.1 3.4 ± 1.3  1 (-5, 6) 0.85 
SUVpeak 6.8 ± 2.0 6.5 ± 2.1 -4 (-10, 2) 0.18 
MTV 587 ± 338 592 ± 361 -2 (-8, 4) 0.51 




1 (-8, 10) 0.84 
Standard deviation 1.4 ± 0.5 1.3 ± 0.5 -5 (-12, 1) 0.12 
Skewness  0.57 ± 0.50 0.41 ± 0.48 -0.15(-0.24, -
0.07) 
0.002 







Entropy 2.4 ± 0.5 2.3 ± 0.5 -4 (-8, 1) 0.11 




-3 (-9, 2) 0.19 
Contrast 0.12 ± 0.06 0.12 ± 0.05 12 (-6, 31) 0.17 
Coarseness (x10-4) 0.8 [0.3, 4.6] 0.9 [0.3, 3.8] 2 (-12, 16) 0.76 
Busyness 13.8 ± 9.9 12.5 ± 10.3 -9 (-21, 3) 0.14 
Complexity 2462 ± 350 2492 ± 392 2 (-3, 6) 0.52 
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Summary statistics for table 18 are: mean (± Standard Deviation), or median [inter-quartile 
range]. 
 
There was a significant decrease in skewness and kurtosis between baseline and 4 weeks post 
therapy (for both of these parameters, the raw change in scores was examined rather than the 
percentage change) with a mean reduction of 0.15 units for skewness, and a median reduction 
of 0.2 units for kurtosis (Figures 20 and 21). 
 







There is a reduction in skewness, but this remains >0 so although values are right skewed, and 
most values concentrated on the left of the mean, this is less marked at 4 weeks than at baseline 
(appears more symmetrically distributed at 4 weeks than baseline). There is a decrease in 
kurtosis from 0.11 at baseline to -0.19 at 4 weeks, so curve becomes less peaked (flat topped). 






Mean SUV 2.38 
4 weeks post treatment 
Skewness: 0.41 
Kurtosis: -0.19 















Figure 21. Change in skewness and kurtosis in the same patient as Figure 20 
 
 
There was also slight evidence that SUVmax values decreased over time, although this difference 
was only of borderline statistical significance (p=0.05).  None of the other parameters were found 
to significantly change from baseline to 4 weeks. Some of the typical changes on other texture 
parameters are shown below (Figure 22). 
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3.2.3 Associations with treatment response and progression based on 
RECIST 
 
According to CT RECIST, at 2 months, 9 participants progressed and 11 did not progress. Those 
patients who progressed had a median PFS and OS of 2 months and 18.5 months, respectively; 
whereas those who did not progress had a median PFS and OS of 4.2 months and 20.8 months, 
respectively. 
 
An initial set of analyses compared the differences in each parameter between patients who 
progressed and those who did not. Analyses were made for the parameters at baseline (Table 
19); 4 weeks (Table 20) and percentage (or absolute) change (Table 21). The data for the majority 
of the parameters was normally distributed, except as previously, uniformity, coarseness, TLG 
and kurtosis. The results indicate that none of the PET parameters at baseline, 4 weeks or 
percentage change were associated with progression according to RECIST criteria. Therefore, no 
further analyses were undertaken. 
 
Table 19 Comparison of parameters at baseline on RECIST in participants who progressed and 
did not progress. 
 
Parameter Participants who did not 
Progress = SD + PR 
n=11 
Participants who 




SUVmax 9.0 ± 3.1 7.8 ± 1.2 0.29 
SUVmean 3.3 ± 1.3 3.4 ± 0.9 0.98 
SUVpeak 7.2 ± 2.6 6.3 ± 1.1 0.36 
MTV 606 ± 357 563 ± 332 0.79 
TLG 1552 [789, 043] 998 [961, 3742] 0.85 
Standard deviation 1.5 ± 0.6 1.2 ± 0.3 0.32 
Skewness  0.66 ± 0.54 0.45 ± 0.47 0.36 
Kurtosis 0.07 [-0.39, 1.25] 0.15 [-0.38, 0.52] 0.79 
Entropy 2.5 ± 0.6 2.4 ± 0.2 0.62 
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Uniformity 0.027 [0.024, 0.037] 0.027 [0.025, 0.031] 0.97 
Contrast 0.12 ± 0.08 0.11 ± 0.04 0.69 
Coarseness (x10-4) 0.7 [0.3, 6.1] 1.0 [0.3, 2.8] 0.85 
Busyness 15.8 ± 10.8 11.5 ± 8.8 0.35 
Complexity 2427 ± 392 2503 ± 309 0.64 
Summary statistics are: mean ± Standard Deviation, or median [inter-quartile range] 
 
Table 20. Comparison of parameters at 4 weeks in RECIST in participants who progressed and did 
not progress. 
 
Parameter Participants who did not 
Progress = SD + PR 
n=11 
Participants who 




SUVmax 8.5 ± 2.9 7.3 ± 1.8 0.28 
SUVmean 3.3 ± 1.4 3.4 ± 1.2 0.93 
SUVpeak 7.0 ± 2.6 5.9 ± 1.3 0.29 
MTV 628 ± 392 548 ± 337 0.63 
TLG 1817 [774, 3555] 1035 [897, 3281] 0.85 
Standard deviation 1.4 ± 0.6 1.2 ± 0.3 0.27 
Skewness  0.52 ± 0.50 0.27 ± 0.46 0.25 
Kurtosis 0.16 [-0.44, 0.59] -0.25 [-0.38, 0.09] 0.57 
Entropy 2.4 ± 0.6 2.2 ± 0.3 0.45 
Uniformity 0.026 [0.022, 0.035] 0.027 [0.026, 0.028] 0.97 
Contrast 0.12 ± 0.06 0.12 ± 0.03 0.85 
Coarseness (x10-4) 0.8 [0.3, 4.9] 1.5 [0.3, 3.5] 0.97 
Busyness 15.7 ± 11.1 8.7 ± 8.3 0.14 
Complexity 2426 ± 458 2573 ± 300 0.42 







Table 21. Comparison of percentage change from baseline to 4 weeks on RECIST in participants 
who progressed and did not progress. 
 
Parameter Participants who did not 
Progress = SD + PR  
n=11 
Participants who 




SUVmax -5 ± 10 -7 ± 16 0.83 
SUVmean 1 ± 12 1 ± 13 0.99 
SUVpeak -3 ± 12 -6 ± 15 0.66 
MTV -1 ± 11 -3 ± 15 0.64 
TLG 0 ± 17 2 ± 24 0.84 
Standard deviation -4 ± 14 -6 ± 15 0.81 
Skewness (*) -0.14 ± 0.15 -0.17 ± 0.23 0.67 
Kurtosis (*) -0.25 [-0.42, 0.02] -0.09 [-0.29, 0.00] 0.85 
Entropy -2 ± 10 -5 ± 9 0.56 
Uniformity -3 ± 10 -4 ± 14 0.93 
Contrast 9 ± 32 17 ± 48 0.67 
Coarseness -2 ± 36 6 ± 21 0.55 
Busyness -5 ± 13 -14 ± 36 0.43 
Complexity 0 ± 7 4 ± 14 0.40 
Summary statistics are: mean ± standard deviation, or median [inter-quartile range] 
(*) Figures for raw change, not percentage change 





3.2.4 Association with progression free survival 
 
Median PFS overall was 3.6 months (mean 5 months), with no survivors at the time of analysis.  
The length of time to progression is shown graphically in the Kaplan-Meier plot in Figure 23 and 
differences in PFS in Figure 24. Looking at participants who progressed on RECIST (with median 
PFS 2 months) and those who did not progress on RECIST (with median PFS 4.2 months), there 
was a statistically significant difference in PFS (p=0.015). 
 














Figure 24. Kaplan-Meier plot of progression free survival on RECIST in participants who 
progressed and did not progress. (p=0.015) 
 
 
Factors associated with PFS were examined and summarised in Table 22 below.  Initially a 
separate association of each texture variable was examined.  Analyses were performed for the 
values at baseline, 4 weeks and also for the percentage (or absolute) change from baseline to 
four weeks. The figures reported are the hazard ratios (HR), and corresponding confidence 
intervals. Due to the different scales for each parameter, hazard ratios are given for a one 
standard-deviation increase in each variable. This indicates the relative change in the risk of 
progression at any time as each texture parameter increases by 1 SD.  P values indicating the 
significance of the results are shown in the final column.  
 
A hazard ration > 1.0 suggests the treatment group has shorter survival. A hazard ratio < 1.0 










Table 22. Univariable analyses for progression free survival 
Timepoint Parameter Hazard Ratio (95% CI) (*) P-value
Baseline SUVmax 1.03 (0.65, 1.61) 0.91
SUVmean 1.54 (0.92, 2.58) 0.1
SUVpeak 1.13 (0.70, 1.82) 0.63
MTV 1.20 (0.75, 1.93) 0.44
TLG 1.32 (0.84, 2.07) 0.23
Standard deviation 1.18 (0.72, 1.93) 0.5
Skewness 0.61 (0.32, 1.19) 0.15
Kurtosis 0.79 (0.47, 1.31) 0.35
Entropy 1.16 (0.70, 1.95) 0.57
Uniformity 0.78 (0.47, 1.29) 0.33
Contrast 1.23 (0.80, 1.92) 0.35
Coarseness 1.16 (0.73, 1.85) 0.54
Busyness 0.91 (0.56, 1.49) 0.7
Complexity 1.23 (0.78, 1.94) 0.38
4 weeks SUVmax 0.97 (0.59, 1.60) 0.92
SUVmean 1.45 (0.83, 2.56) 0.19
SUVpeak 0.99 (0.59, 1.67) 0.98
MTV 1.17 (0.73, 1.86) 0.52
TLG 1.32 (0.83, 2.11) 0.24
Standard deviation 0.96 (0.58, 1.59) 0.88
Skewness 0.56 (0.26, 1.18) 0.13
Kurtosis 0.92 (0.56, 1.49) 0.73
Entropy 0.93 (0.55, 1.56) 0.78
Uniformity 0.94 (0.62, 1.44) 0.78
Contrast 1.03 (0.68, 1.56) 0.89
Coarseness 1.12 (0.70, 1.79) 0.64
Busyness 0.83 (0.50, 1.37) 0.47
Complexity 1.03 (0.68, 1.56) 0.88
% change baseline to 4 weeks SUVmax 0.79 (0.46, 1.33) 0.37
SUVmean 0.76 (0.46, 1.27) 0.29
SUVpeak 0.71 (0.44, 1.16) 0.17
MTV 1.14 (0.64, 2.01) 0.66
TLG 0.89 (0.51, 1.56) 0.68
Standard deviation 0.56 (0.34, 0.94) 0.03
Change baseline to 4 week Skewness 1.03 (0.62, 1.73) 0.91
Change baseline to 4 week Kurtosis 1.59 (0.86, 2.97) 0.14
% change baseline to 4 weeks Entropy 0.65 (0.41, 1.03) 0.07
Uniformity 2.30 (1.13, 4.67) 0.02
Contrast 0.73 (0.36, 1.51) 0.4
Coarseness 0.93 (0.52, 1.66) 0.81
Busyness 0.86 (0.42, 1.80) 0.7
Complexity 0.71 (0.38, 1.32) 0.28   
99 
 
The results suggested that there was no strong evidence that any of the texture parameters at 
baseline or at 4 weeks were associated with progression.  
 
The analyses for the change in values from baseline to four weeks suggested that an increase in 
SD was associated with a decreased risk in progression (HR 0.56); conversely a decrease in SD 
was associated with increased risk of progression (as increase in S D results in a lower risk). 
 
Increase in uniformity (or lesser decrease) was significantly associated with progression (HR 2.3), 
hence that texture features become more homogeneous after ADI therapy, but patients have 
reduced PFS (which is contrary to previously published literature with other treatments in other 
tumour types). 11/20 patients had talc pleurodesis and 5/20 had calcified pleural plaques. These 
are not expected to have had an effect on PET texture features, as would not change with 
therapy. 
 
Multi-variable analysis found collinearity between entropy and SD. Although SD was found to be 
the most significant factor in the univariable analysis, this variable was excluded and entropy was 
included in the multivariable analysis, as entropy was regarded as the most clinically useful 
variable with more previous evidence in the literature of utility. A backwards selection procedure 
was performed to retain only variables found to have some relationship with time to progression. 
Uniformity, which had been significant in the univariable analysis, was not longer significant in 
the multi-variable analysis for PFS.  The final model is summarised in Table 23. 
 
Table 23. Multi-variable analyses for progression free survival 
Timepoint Parameter Hazard Ratio (95% CI) (*) P-value
Baseline SUVmean 1.58 (0.98, 2.56) 0.06
Change to 4 weeks SUVpeak (+) 0.51 (0.28, 0.94) 0.03
Kurtosis (++) 1.96 (1.01, 3.79) 0.05  
(*) Hazard ratios are reported for a one standard deviation increase in each parameter 
(+) Percentage change in values 




The main finding was that a greater percentage increase in SUVpeak was associated with a HR of 
0.51 (decreased risk); hence reduction in SUVpeak from baseline to 4 weeks was associated with 
a greater risk of progression (one SD reduction in this variable was associated with a doubling of 
the risk of progression, p=0.03), suggesting that the SUV post treatment reduces and hence the 
treatment is having a pharmacological effect, however, this does not translate into improved 
survival. This is an unexpected finding. A Kaplan-Meier plot of the dichotomised data around the 
median value reveals p=0.67, hence this was not significant (Figure 25). 
 
Figure 25. Kaplan-Meier plot of progression free survival above and below median SUVpeak % 
change from baseline to 4 weeks (p=0.67) 
 
 
There were two further findings of borderline significance: one that higher baseline values of 
SUVmean were associated with an increased progression risk (a one SD increase in this variable 
was associated with a 58% increase in the risk of progression at any time); also that an increase 
in kurtosis from baseline to 4 weeks post therapy was associated with increased PFS (one SD 
increase in kurtosis was associated with an almost doubling of the risk). Kaplan-Meier plot of the 
dichotomised data around the median values for baseline SUVmean and change in kurtosis were 
p=0.12 and p=0.14, respectively, hence also not significant (Figures 26 and 27). After adjusting 
for these variables, there was no longer any significant association between any further factors 
and time to progression. 
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Figure 27. Kaplan -Meier plot of progression free survival above and below median kurtosis 






3.2.5 Association with overall survival 
 
Median OS was 18.9 months (mean 20.2 months), with no survivors at the time of analysis.  The 
length of time to progression is shown graphically by the Kaplan-Meier plot in Figure 28 and 
differences in OS in Figure 29. Looking at participants who progressed on RECIST (with median 
OS 18.5 months) and participants who did not progress on RECIST (with median OS 20.8 months), 
there was no statistically significant difference in OS (p=0.334). 
 

































Figure 29. Kaplan-Meier plot of overall survival on RECIST in participants who progressed and did 
not progress. (p=0.33) 
 
The association between texture variables and overall survival times was examined. Initially the 
separate association between each texture variable at baseline, 4-week percentage change and 
the outcome were examined separately in a series of univariable analyses. The analysis results 
are summarised in Table 24. As with PFS, the hazard ratios are reported for a one SD increase in 
each of the texture variables. 
 
Univariable analysis suggested that a number of the texture variables at baseline were 
significantly associated with OS times (unlike PFS which was not affected). Baseline SUVmean, 
SUVpeak, MTV and TLG were all found to be significantly associated with OS. Additionally, there 
was some evidence that baseline SUVmax, SD and entropy could predict OS, however, the results 
for these variables were not quite statistically significant. Higher values of all these variables 
were associated with an increased risk of death at any time. The largest effect was for TLG, where 
a one SD increase was associated with a 2.5-fold increase in the risk of death at any time.  
 
Of the texture variables at 4 weeks, only MTV and TLG were significantly associated with OS. 
Large values of both these variables were associated with an increased risk of death with a one 
SD increase in MTV associated with a 1.9-fold increase in risk and a 1 SD increase in TLG 




There was no evidence that the percentage change in any of the texture variables was significant 





Table 24. Univariable analyses for overall survival 
Timepoint Parameter Hazard Ratio (95% CI) (*) P-value
Baseline SUVmax 1.58 (0.92, 2.72) 0.10
SUVmean 1.90 (1.08, 3.36) 0.03
SUVpeak 1.84 (1.04, 3.26) 0.04
MTV 2.01 (1.16, 3.48) 0.01
TLG 2.58 (1.41, 4.70) 0.002
Standard deviation 1.74 (0.98, 3.11) 0.06
Skewness 0.66 (0.37, 1.19) 0.17
Kurtosis 0.82 (0.46, 1.47) 0.51
Entropy 1.69 (0.94, 3.06) 0.08
Uniformity 0.88 (0.50, 1.57) 0.69
Contrast 1.18 (0.67, 2.09) 0.56
Coarseness 0.91 (0.54, 1.53) 0.73
Busyness 1.39 (0.84, 2.31) 0.20
Complexity 1.06 (0.62, 1.83) 0.83
4 weeks SUVmax 1.54 (0.86, 2.74) 0.15
SUVmean 1.61 (0.90, 2.86) 0.11
SUVpeak 1.49 (0.84, 2.63) 0.17
MTV 1.86 (1.10, 3.15) 0.02
TLG 2.21 (1.26, 3.86) 0.005
Standard deviation 1.34 (0.80, 2.24) 0.27
Skewness 0.74 (0.41, 1.33) 0.32
Kurtosis 0.95 (0.54, 1.67) 0.86
Entropy 1.29 (0.75, 2.22) 0.36
Uniformity 1.08 (0.66, 1.76) 0.76
Contrast 0.85 (0.54, 1.32) 0.47
Coarseness 0.81 (0.49,1.32) 0.40
Busyness 1.20 (0.74, 1.96) 0.45
Complexity 0.88 (0.53, 1.45) 0.61
% change baseline to 4 weeks SUVmax 0.93 (0.56, 1.56) 0.79
SUVmean 0.74 (0.43, 1.26) 0.27
SUVpeak 0.76 (0.48, 1.23) 0.26
MTV 1.22 (0.78, 1.90) 0.39
TLG 1.09 (0.64, 1.87) 0.74
Standard deviation 0.76 (0.48, 1.21) 0.25
Change baseline to 4 week Skewness 1.34 (0.81, 2.22) 0.25
Change baseline to 4 week Kurtosis 1.28 (0.76, 2.16) 0.36
% change baseline to 4 weeks Entropy 0.79 (0.52, 1.21) 0.28
Uniformity 1.44 (0.86, 2.40) 0.16
Contrast 0.71 (0.37, 1.34) 0.29
Coarseness 0.79 (0.45, 1.38) 0.41
Busyness 0.92 (0.45, 1.89) 0.83
Complexity 0.72 (0.38, 1.36) 0.31  
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Multi-variable analysis revealed collinearity between all of SUVmax, SUVmean, SUVpeak, SD and 
entropy at baseline, with all variables strongly positively correlated. SUVmax and entropy were 
included in the multivariable analyses, as these were clinically important factors with supportive 
evidence from previous literature. There was also found to be evidence of collinearity between 
MTV and TLG at baseline and 4 weeks, which is not surprising as TLG = MTV x SUVmean. TLG was 
found to be the strongest predictor in the univariable analysis, so was retained in the multi-
variable analysis, with MTV omitted.  
 
A backwards selection procedure (fitting regression model) of the remaining variables was 
performed. This found that only TLG at baseline was independently significantly associated with 
OS times (p=0.002). After adjusting for this variable, no further variables were found to be 
statistically significant. As this was the only variable in the final model, the size of the relationship 
between this variable and survival times was equivalent to that observed in the univariable 
analysis. A Kaplan-Meier plot of the dichotomised data around the median TLG value reveals 
p=0.006 (Figure 30), hence significant (and better than CT RECIST as this was not significant). 
Those with larger tumours with higher uptake (> median) had median survival of 11 month; those 
with smaller tumours with low uptake (< median) had median survival of 27 months.  
 
Figure 30. Kaplan-Meier plot of overall survival above and below median TLG at baseline 
(p=0.006) 
 
1 is > median TLG, (larger 
tumours with high uptake) 
 
2 is < median TLG 
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3.2.6 Texture parameter association with MTV  
 
The mean MTV of the primary tumours was 627.7 ml at baseline (+/- 398.2 ml) and 565.4 ml at 
4 weeks (+/- 381.3 ml). SUV parameters were associated with MTV (Table 25) as large tumours 
tend to demonstrate high SUVs. A minimum volume of 10mls needs to be reached before texture 
is affected (114).  In this study the tumour volumes were large and above the minimum 
threshold, hence the partial volume effect is unlikely to be a factor here. 
 







SUVmax 0.41 0.08 0.42 0.06
SUVmean 0.55 0.01 0.22 0.36
SUVpeak 0.51 0.02 0.34 0.14
Standard 0.37 0.11 0.34 0.14
Entropy 0.46 0.04 0.41 0.07
Uniformity -0.3 0.2 0.09 0.69
Coarseness -0.51 0.02 -0.65 0.002
Contrast -0.11 0.63 -0.52 0.02
Busyness 0.84 <0.001 0.66 0.002
Complexity 0.17 0.48 -0.03 0.91
TLG 0.92 <0.001 0.82 <0.001
Skewness (*) -0.53 0.02 0.16 0.5
Kurtosis (*) -0.4 0.08 0.27 0.26
Baseline % change baseline to 4 wks
 
(*) Figures for raw change, not percentage change 
 
 
The results suggested that a number of the texture variables at baseline were significantly 
associated with baseline MTV, including SUVmean (Figure 31) and SUVpeak, entropy, coarseness 
and notably busyness (r=0.84, p<0.001, Figure 32); so large tumours are more heterogeneous, 
more metabolically active and less coarse.  Additionally, the percentage change in MTV was also 
significantly associated with the changes in high order variables including contrast, coarseness 
and busyness (r=0.66, p=0.002, Figure 33). 
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At baseline and change from baseline to 4 weeks, the strongest association with MTV was with 
TLG (r=0.92 and r=0.82, respectively), which is irrelevant as TLG= MTV x SUVmean. 
 
Figure 31. Correlation of baseline SUV mean and MTV (p=0.01) (r=0.55; r2=0.29) 
 
 












3.2.7 Summary of results 
 
From baseline to 4 weeks post therapy, there was decrease in skewness (mean 0.15 units, 
p=0.002) and kurtosis (median 0.2 units, p=0.03). None of the parameters at baseline or post 
therapy were associated with progression according to RECIST criteria (modified RECIST response 
at 2 months). 
 
The median PFS in all participants was 3.6 months. PFS (which reflects treatment effect) differed 
between progressors (n=9) on RECIST (median PFS 2 months) and non-progressors (n=11) on 
RECIST (median PFS 4.2 months), p=0.015; although OS did not. 
In terms of PFS, on univariable analysis, an increase in uniformity (or lesser decrease) was 
associated with progression (hazard ratio 2.3, p=0.02); similarly an increase in standard deviation 
was associated with decreased risk of progression (hazard ratio 0.56, p=0.03); hence that texture 
features become more homogeneous after ADI therapy, but patients have reduced PFS (which is 
contrary to previously published literature with other treatments in other tumour types). On 
multivariable analysis a greater percentage increase in SUVpeak from baseline to 4 weeks was 
associated with a decreased risk of progression (hazard ratio 0.51, p=0.03). 
 
The median OS in all participants was 18.9 months. Baseline SUVmean (p=0.03), SUVpeak 
(p=0.04), metabolic tumour volume (MTV) (p=0.01) and total lesion glycolysis (TLG) (0.002) were 
all associated with OS (hence these predict nature of the tumour but not drug/therapy effect). 
At four weeks, only MTV and TLG were significantly associated with OS with 1.9 and 2.2-fold 
increased risk in death, respectively. On multi-variable analysis, TLG at baseline was 
independently significantly associated with OS (p=0.002) and better than RECIST (p=0.334) 
 
Associations with MTV include busyness (r=0.84) and SUVmean and peak, entropy, coarseness 
at baseline (large tumours are more heterogeneous, hotter and less coarse); whereas high order 
features such as contrast, coarseness and busyness were associated with change in MTV from 
baseline to 4 weeks. 
 
Arginine deprivation therapy shows some increased homogeneity in texture features, but this 





Between baseline and 4 weeks, there is a significant decrease in skewness in the distribution of 
FDG uptake in mesotheliomas treated with arginine deprivation therapy. Skewness reflects 
asymmetry of histogram distribution. In our study, skewness is positive at baseline, hence most 
values are concentrated on the left of the mean, with extreme values to the right; whereas at 4 
weeks the skewness reduces (but remains positive), so the histogram of SUV values is more 
symmetrically distributed.   
 
Kurtosis reflects the sharpness/peakedness/pointedness of histogram distribution, the wider the 
histogram, the lower/negative the kurtosis. It is also a measure of how outlier-prone a 
distribution is. The kurtosis of the normal distribution is 3. In this study kurtosis was 0.11 at 
baseline, hence <3 and in keeping with a platykurtic distribution (flatter than a normal 
distribution with a wider peak). This decreases further post therapy a hence further flattening of 
the peak (as shown in the results section). However, kurtosis post therapy also becomes 
negative, so it is considered to be a “light-tailed” dataset with as much data in each tail as it does 
in the peak (and therefore less extreme values). 
 
The published literature does not describe changes in kurtosis and skewness post treatment, but 
has described changes in SUVmean, SUVmax, SD and entropy, in NSCLC post treatment (102). 
We also saw a borderline decrease in SUVmax from mean 8.5 to 8.0, however this change is too 
small to suggest a definite therapy effect. 
 
In our study, no PET texture parameters at baseline, 4 weeks post treatment or percentage 
change from baseline to 4 weeks predicted progression according to RECIST data. In a study by 
Cook et al.(102), none of the PET parameters at baseline or in that study at 6 weeks post 
treatment, were associated with RECIST response at 12 weeks either, however, percentage 
changes in SUVmax, SD, entropy and uniformity were associated with response. In this study, 
therapy was with erlotinib, which is a tyrosine kinase inhibitor and the study looked at NSCLC 
whereas ADAM looked at arginine deprivation therapy in MPM.  Entropy is a statistical measure 
of randomness that can characterize the heterogeneity of the tumour, hence a treatment 
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response was associated with a decrease in heterogeneity, as one would expect. In the same 
study, increase in uniformity was associated with response.  
 
In patients with NSCLC receiving either conventional radiation therapy or stereotactic body 
radiation therapy (SBRT), a number of first-order features on FDG PET-CT were able to predict 
for local and locoregional control with a model of combined PET and CT features as predictors 
(101). However, radiation therapy has a very different effect than arginine deprivation therapy. 
SBRT uses very focused beams of high dose radiation (with fewer treatments) aimed at the 
tumour from different angles to damages the cancer cells by breaking the DNA.  
 
In our study, median and mean PFS were 3.6 and 5 months, respectively with no survivors at the 
time of analysis. PFS differed between those who progressed (n=9) on RECIST (median PFS 2 
months) and those who did not progress (n=11) on RECIST (median PFS 4.2 months), although 
OS did not.  
 
In terms of PFS, on univariate analysis, a decrease in SD was associated with increased risk of 
progression. Increase in uniformity (or lesser decrease) was significantly associated with 
progression, hence that texture features become more homogeneous after ADI therapy, but 
patients have reduced PFS. This is contrary to previously published literature in NSCLC (102) 
where uniformity at 6 weeks was associated with increased survival, albeit OS rather than PFS.  
 
Multi-variable analysis of PFS found that uniformity was no longer significant. Now, a greater 
percentage reduction in SUVpeak from baseline to 4 weeks was associated with a greater risk of 
progression in terms of PFS (one SD reduction in this variable was associated with a doubling of 
the risk of progression, p=0.03) suggesting the treatment was having a pharmacological effect, 
but this does not translate into improved survival, which is an unexpected finding.  Possible 
explanations for this include false positives from talc pleurodesis (present in 11/20 of the 
patients); calcified plaques (present in 5/20); variation in outlining the lesions (however this is 
unlikely as would affect all groups); or a real finding (although this is not easily explained 
biologically with reference to FDG distribution within a tumour).  The effect of talc pleurodesis 
on texture features is unknown, but this is not expected to have an effect. It may be that the 
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patients had significant co-morbidity, as they had exhausted all other available treatment 
options, before commencing on the ADAM trial. 
 
Most studies in the published literature deal with OS rather than PFS. In our study, median and 
mean OS was 18.9 months and 20.2 months, respectively and showed that a number of the 
texture variables at baseline were significantly associated with survival including SUVmean 
(p=0.03), SUVpeak (p=0.04), MTV (p=0.01) and TLG (p=0.002). Additionally, there was some 
evidence that SUVmax (p=0.1), SD (p=0.06) and entropy (p=0.08) were also prognostic, although 
not quite statistically significant. The largest effects were for TLG where a one SD increase was 
associated with a 2.5-fold increase in the risk of death and MTV with doubling risk of death. At 4 
weeks, MTV and TLG were also significantly associated with OS with 1.9 and 2.2-fold increased 
risk in death, respectively. On multi-variable analysis, TLG at baseline was independently 
significantly associated with OS (p=0.002) and better than RECIST (p=0.334). This is consistent 
with the published data from Klabatsa et al. (105) which showed that FDG parameters which take 
account of MTV and TLG show significant associations with OS in patients with MPM.  Cook et al. 
also found that a 10% increase in entropy was associated in a 14% increased risk of death (this 
was of borderline significance in our study) and a high-order feature, contrast, was associated 
with an 80% risk of death (102). Other studies have also shown that other high-order features, 
in particular, coarseness, have shown predictive and prognostic capability in NSCLC patients who 
underwent chemoradiation therapy, namely that patients with PET images showing relatively 
uniform tracer distribution (high contrast, low coarseness) were more likely to respond to 
treatment (100).  
 
A retrospective study of 26 patients with stage 1 NSCLC tested standard metrics and texture 
parameters in pretherapy (SBRT) PET-CT scans for the prediction of progression-free and OS 
(115). Only SUVmax was predictive for progression-free survival (p=0.03), with no PET 
parameters found for OS on univariate analysis. A larger study of 63 patients with NSCLC who 
underwent SBRT tested standard metrics and 13 texture features in FDG PET-CT for disease 
specific and OS (116). On multi-variable analysis, only dissimilarity, a second-order feature was 
associated with disease-specific and disease-free survival (hazard ratio 0.822, P =0 .037; hazard 




The literature has suggested the possible dependence of certain texture features on tumour 
volume. In our study, the median MTV of the primary tumours was 596.5 ml at baseline (range: 
55.6 -1296.7) and 633.0 ml at 4 weeks (range: 49.3 – 1355.1). SUV parameters are associated 
with MTV as large tumours demonstrate high SUV. Brooks and Grigsby, using probability theory, 
calculated that local (second) order entropy from cervical tumour volumes of <45 cm3 can be 
very sensitive to size, and may reflect size rather than underlying heterogeneity (117) and also 
reported that second-order entropy is 5 times more sensitive to changes in volumes below 
45cm3.  Hatt et al. (114) found second-order entropy showed high correlation in volumes of <10 
cm3 but much less at volumes >10 cm3. The minimal volume to consider may therefore be closer 
to 10 cm3 than 45 cm3.  In our study the tumour volumes are large and above the minimum 
threshold, hence the partial volume effect is unlikely to be a factor. 
 
Our study found that associations with MTV include busyness (r=0.84) and SUVmean and peak, 
entropy, coarseness at baseline; so large tumours are more heterogeneous, hotter and less 
coarse. Larger tumours are known to exhibit higher hypoxia, necrosis, or anatomic and 
physiologic complexity at the microscopic and macroscopic scales, which translates to higher 
complexity in the spatial distribution of FDG uptake and consequently associated heterogeneity 
quantification (114). The association with entropy has been highlighted in the literature (as 
above), but was not shown by Cook et al. in NSCLC (102). However, they also describe 
associations between MTV and high-order features including busyness and coarseness (but also 
contrast). Our study also found that high-order features such as contrast, coarseness and 










Texture analysis methodology varies between manually drawn regions of interest (which are 
subject to the greatest inter- and intra-observer variability) to automatic or semiautomatic 
methods, such as using a fixed percentage threshold of SUVmax, commonly 40%, to more 
sophisticated methods such as fuzzy locally adaptive Bayesian methods(114) . Analysis in our 
study was all with manually drawn regions of interest, which risks associated error from possibly 
including ”normal” lung, pleura or rib, rather than just disease.  However, it was not possible to 
use automated methods due to the extensive volume of disease and difficulty in separating from 
uptake in ribs.  The ROIs were also only drawn by one clinician, so there are no interobserver 
measurements. Also, the numbers were small, with only 20 patients.  There is no published 
literature to date of FDG PET-CT texture features in mesothelioma treatment response for 
comparison. 
 
A major limitation in this substudy is that we only had 20 participants and thus the study is too 
small a population for radiomics evaluation as the number of parameters may be exceeding the 
number of participants – which will increase the false discovery rate.  In addition, no correction 
was applied to correct for multiple comparisons and “control” the false discovery rate (neither 




By 4 weeks, no first-order PET parameters predict CT RECIST response at 2 months, however, 
MTV and TLG are prognostic for OS (with 1.9 and 2.2-fold increased risk of death, respectively). 
Increase in uniformity was associated with progression (hazard ratio 2.3, p=0.02) and increase in 
standard deviation was associated with decreased risk of progression (hazard ratio 0.56, p=0.03); 
hence that texture features become more homogeneous after ADI therapy, but patients have 
reduced PFS Arginine deprivation therapy is having a pharmacological effect, with some 






The TRAP substudy revealed that tumour proliferation imaging (using FLT PET-CT) undertaken 
within 12 hours of arginine deprivation therapy in thoracic malignancy can predict end of 
treatment CT (RECIST) response in nearly 2/3 cases, hence it is a marker of treatment response. 
However, ANOVA analysis reveals no significant evidence that a decrease in proliferation 
(measured as SUVmax on FLT PET-CT) precedes a decrease is size RECIST length, hence it is not a 
reliable marker of early treatment response and offers no real advantage over conventional CT 
imaging.  Interestingly, when using end of treatment CT as the gold standard, the response to 
ADIPEMCIS therapy as demonstrated on FLT PET-CT is greater than on end of treatment CT (mean 
decrease of 36.5% in SUVmax compared to 21.9% decrease in RECIST length).  
 
The TRAP phase 1 trial overall revealed a 94% disease control rate in non-epithelioid (biphasic 
and sarcomatoid) MPM subtypes characterized by a 75% rate of ASS1 loss. This has led to the 
ATOMIC-Meso, a phase 2/3 study looking at the role of targeted arginine deprivation again in 
combination with cisplatin and pemetrexed in aggressive subtypes of mesothelioma, with 
patients assessed every 6 weeks on CT imaging using modified RECIST criteria to assess treatment 
response (118). 
 
Tumour heterogeneity, as assessed using texture features on FDG PET-CT at baseline and 4 
weeks, did not predict CT RECIST response at 2 months to arginine deprivation treatment (ADAM 
trial). However, MTV and TLG are prognostic for OS (with 1.9 and 2.2-fold increased risk of death, 
respectively) indicating that arginine deprivation therapy is having a pharmacological effect, with 
some increased homogeneity in texture features, but this does not translate into improved 
survival. 
 
Radiomics allow us to extract multiple ‘unseen’ features from images, which can provide 
additional information that allows better tumour characterization, treatment prediction and 
prognostication. However, the requirement for dealing with increasingly large amounts of data 
from medical images has led to the increasing interest in artificial intelligence (AI), which is 
related to improvements in computing power and advances in machine learning (ML). ML is a 
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powerful and flexible tool that has wide medical imaging applications beyond the assessment of 
tumour heterogeneity and biology. Use of AI for automated tumour detection, segmentation, 
biological assessment, automated interpretation of findings and clinical decision support through 
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Scanner stability and background checks in TRAP substudy 
 
QC data using SUV mean phantom measurement for March 2015-mid July 2016 (Figure34) 
demonstrated good PET-CT camera stability. SUVmean used rather than SUVmax thought to be 
more consistent for large area phantom measurements. The SUVmean was 1.006 (±0.004). 
The majority of FLT PET/CT scans were undertaken in this time period.  
 







Background FLT variation on PET/CT 
 
Measurements of background FLT uptake (using SUVmax) in bone marrow (BM) in the L1 
vertebral body (Figure 35) and other background regions including liver (Figure 36); mediastinal 
blood pool (MBP) (Figure 37); and muscle (Figure 38).  These provide a measure of biological 
variability (which may or may not be affected by the therapy) and were obtained for all the cases 
of MPM and the first four cases of NSCLCs.  
We also calculated ratios of BM/MBP, and BM/liver, but this did not provide any additional useful 
data. 
 
The results confirm that there is only small biological variability. 
 




Bone marrow (BM) uptake demonstrated considerable variation, although the majority of 
values lay between 75% and 125 % of baseline. There is intense FLT accumulation in BM, this 






Figure 36. Proliferation imaging in liver 
 
 
Liver uptake also demonstrated variation, although less than BM and the majority of values lay 
between 80% and 120%. As there is usually intense hepatic uptake with FLT, this variation could 
relate to measurement error, noise, biological variation, or a combination. 
 
 Figure 37. Proliferation imaging in MBP 
 
 
MBP uptake was generally low grade (SUVmax <1) and again demonstrated variation, with values 








Muscle uptake was also generally low grade (SUVmax <1) with values lying between 80% and 








Appendix B  
 
Radiation exposure in the TRAP substudy 
 
The effective Dose (ED) of radiation per FLT PET scan was approximately 8.5 mSv per FLT PET (as 
calculated by L.P, senior clinical scientist). Patients who received a total of 4 FLT PETs had a 
cumulative exposure from this dose of approximately 34 mSv. The low dose CT of the neck, chest 
and abdomen used for attenuation correction and anatomical correlation results in additional 
radiation exposure of 9 mSv per CT scan and the cumulative exposure from 4 low dose CTs was 
36 mSv. Hence, the total ED for the 4 FLT PET-CT scans was 70 mSv. 
 
 
